<SEC-DOCUMENT>0001213900-25-121461.txt : 20251215
<SEC-HEADER>0001213900-25-121461.hdr.sgml : 20251215
<ACCEPTANCE-DATETIME>20251215075018
ACCESSION NUMBER:		0001213900-25-121461
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20251212
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251215
DATE AS OF CHANGE:		20251215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RELMADA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001553643
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				455401931
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39082
		FILM NUMBER:		251570054

	BUSINESS ADDRESS:	
		STREET 1:		2222 PONCE DE LEON BLVD. 3RD FLOOR
		CITY:			CORAL GABLES
		STATE:			FL
		ZIP:			33134
		BUSINESS PHONE:		646 876 3459

	MAIL ADDRESS:	
		STREET 1:		2222 PONCE DE LEON BLVD. 3RD FLOOR
		CITY:			CORAL GABLES
		STATE:			FL
		ZIP:			33134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CAMP NINE, INC.
		DATE OF NAME CHANGE:	20120706
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0269660-8k_relmada.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:RLMD="http://relmada.com/20251212">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_RLMD_relmada.com_20251212 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20251212_20251212 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001553643 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000004" name="dei:EntityCentralIndexKey">0001553643</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rlmd-20251212.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-12-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-12</xbrli:startDate>
        <xbrli:endDate>2025-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM&#160;<span id="xdx_903_edei--DocumentType_c20251212__20251212_z7h0rbrfMK6c"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Pursuant to Section
13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Securities Exchange
Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date of
earliest event reported):&#160;<b><span id="xdx_901_edei--DocumentPeriodEndDate_c20251212__20251212_zG4Oix3hChPi"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December 12, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span id="xdx_902_edei--EntityRegistrantName_c20251212__20251212_zR0ZWLtaeyP2"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000011" name="dei:EntityRegistrantName">RELMADA THERAPEUTICS,
INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20251212__20251212_zlgR53ykkVAd"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20251212__20251212_zJvT9HnCzMLh"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000013" name="dei:EntityFileNumber">001-39082</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20251212__20251212_z1aIlhOATxt2"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000014" name="dei:EntityTaxIdentificationNumber">45-5401931</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20251212__20251212_zzNh12ox5SAb"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000015" name="dei:EntityAddressAddressLine1">2222 Ponce de Leon Blvd.</ix:nonNumeric></span>,<span id="xdx_900_edei--EntityAddressAddressLine2_c20251212__20251212_zmfK8HRrweoi"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000016" name="dei:EntityAddressAddressLine2">&#160;Floor 3</ix:nonNumeric></span><br/>
<span id="xdx_90C_edei--EntityAddressCityOrTown_c20251212__20251212_zbtEhdZXOwA7"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000017" name="dei:EntityAddressCityOrTown">Coral Gables</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20251212__20251212_zhIKQbUdfg26"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000018" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: top; width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20251212__20251212_zNROEsXnBzr7"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000019" name="dei:EntityAddressPostalZipCode">33134</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code:&#160;<b>(<span id="xdx_907_edei--CityAreaCode_c20251212__20251212_zHFttHgrvKQ1"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000020" name="dei:CityAreaCode">786</ix:nonNumeric></span>)&#160;<span id="xdx_90C_edei--LocalPhoneNumber_c20251212__20251212_zi55UkEWkyS8"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000021" name="dei:LocalPhoneNumber">629-1376</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; width: 100%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Former name or former address, if changed since last report)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20251212__20251212_zIWwpnj46c9l"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--SolicitingMaterial_c20251212__20251212_zPhdj4otHsI4"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementTenderOffer_c20251212__20251212_zDsXjMdjQRBg"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20251212__20251212_zU0sWfEbpuS1"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Securities registered
pursuant to Section&#160;12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt">Trading Symbol&#160;</span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt">Name of exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--Security12bTitle_c20251212__20251212_z1axdjodZDtk"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000026" name="dei:Security12bTitle">Common stock, $0.001 par value per share</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--TradingSymbol_c20251212__20251212_zrsqZw6Geelg"><ix:nonNumeric contextRef="AsOf2025-12-12" id="Fact000027" name="dei:TradingSymbol">RLMD</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>The&#160;<span id="xdx_90F_edei--SecurityExchangeName_c20251212__20251212_zOEI3p1uunMf"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20251212__20251212_zGMouHFf6gAg"><ix:nonNumeric contextRef="AsOf2025-12-12" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><b></b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><b>&#160;</b></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.75in"><b>Item&#160;5.02</b></td><td style="text-align: justify"><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.&#160;</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 12, 2025,
the Board of Directors the Board of Directors of Relmada Therapeutics, Inc. (the &#8220;Company&#8221;) approved an amended and restated
employment agreement with each of its executive officers, each to become effective as of January 1, 2026. Except as described below, the
material terms of each executive officer&#8217;s employment agreement, as amended, are unchanged from those described in the Company&#8217;s
definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2025, under the caption &#8220;<i>Executive
Compensation&#8212;Employment Agreements</i>&#8221; (in the case of Sergio Traversa, Maged Shenouda and Charles Ence) or in the Company&#8217;s
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 6, 2025 (in the case of Paul Kelly), which descriptions
are incorporated herein by reference,.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Sergio Traversa, Chief
Executive Officer</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Mr. Traversa&#8217;s salary will increase from $787,787 to $827,176 per year.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Paul Kelly, Chief
Operating Officer</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Mr. Kelly&#8217;s salary will increase from $499,800 to $524,790 per year.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In the event of termination other than for cause or resignation for good reason (other than as described
in the next bullet), Mr. Kelly will be entitled to severance equal to twelve months of compensation (at the salary plus target bonus rate
in effect as of the date of termination) payable in a lump sum.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In the event of termination other than for cause or resignation for Good Reason, in each case during the
12-month period beginning on the date of a Change in Control (as defined in the Company&#8217;s 2021 Stock Option and Equity Incentive
Plan, as amended), Mr. Kelly will be entitled to severance equal to 18 months of compensation (at the salary plus target bonus rate in
effect as of the date of termination) payable in a lump sum.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In either of the foregoing events, Mr. Kelly will be entitled to continuation of health benefits for twelve
months.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Maged Shenouda (Chief
Financial Officer)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Mr. Shenouda&#8217;s salary will increase from $558,990 to 586,940 per year.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In the event of termination other than for cause or resignation for good reason (other than as
                                                                    described in the next bullet), Mr. Shenouda will be entitled to severance equal to twelve months of compensation (at the salary plus
                                                                    target bonus rate in effect as of the date of termination) payable in a lump sum.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In the event of termination other than for cause or resignation for Good Reason, in each case during the
12-month period beginning on the date of a Change in Control, Mr. Shenouda will be entitled to severance equal to 18 months of compensation
(at the salary plus target bonus rate in effect as of the date of termination) payable in a lump sum.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In either of the foregoing events, Mr. Shenouda will be entitled to continuation of health benefits for
the longer of twelve months or until he becomes eligible for Medicare coverage (Part A or Part B) and is at least 65 years of age.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i><span style="text-decoration: underline">Charles Ence, Chief
Accounting and Compliance Officer</span></i><span style="text-decoration: underline">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Mr. Ence&#8217;s salary will increase from $548,990 to $576,440 per year.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In the event of termination other than for cause or resignation for good reason (other than as described
in the next bullet), Mr. Ence will be entitled to severance equal to twelve months of compensation (at the salary plus target bonus rate
in effect as of the date of termination) payable in a lump sum.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In the event of termination other than for cause or resignation for Good Reason, in each case during the
12-month period beginning on the date of a Change in Control, Mr. Ence will be entitled to severance equal to 18 months of compensation
(at the salary plus target bonus rate in effect as of the date of termination) payable in a lump sum.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing descriptions (including the descriptions
incorporated by reference) of each executive officer&#8217;s amended and restated employment agreement are qualified in their entirety
by reference to the full text of each such agreement, copies of which are filed as Exhibits 10.1 through 10.4 to this Current Report on
Form 8-K and are incorporated herein by reference.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.75in"><b>Item 9.01.</b></td><td style="text-align: left"><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">(d)&#160;<span style="text-decoration: underline">Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: left"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 90%; text-align: left"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">10.1*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea026966001ex10-1_relmada.htm"><span style="font-size: 10pt">Amended and Restated Employment Agreement, effective as of January 1, 2026, between Relmada Therapeutics, Inc. and Sergio Traversa</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">10.2*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea026966001ex10-2_relmada.htm"><span style="font-size: 10pt">Amended and Restated Employment Agreement, effective as of January 1, 2026, between Relmada Therapeutics, Inc. and Paul Kelly</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">10.3*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea026966001ex10-3_relmada.htm"><span style="font-size: 10pt">Amended and Restated Employment Agreement, effective as of January 1, 2026, between Relmada Therapeutics, Inc. and Maged Shenouda</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">10.4*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea026966001ex10-4_relmada.htm"><span style="font-size: 10pt">Amended and Restated Employment Agreement, effective as of January 1, 2025, between Relmada Therapeutics, Inc. and Charles Ence</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">104</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Dated: December 15, 2025</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt"><b>RELMADA THERAPEUTICS, INC.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 60%; text-align: justify">&#160;</td>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="width: 35%; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><i>/s/ Sergio Traversa</i></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Name:</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Sergio Traversa</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Title:</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZi/1TF11atIhVSinidrCpDLaTkhn/juQtnbaIIRCS974XIWYio61qkeG8LnOosOtbaRFKbJBRX9A50t0+ATdLvCpjWWo7rj8wJcegY1bzWLr76Hwog3UCYeSHCz9aQhgkQQzFQXiDnpJuVI3aKtmC1DUUTD0rtJLfU0IlX6Spe4+fTshGkXZx82CSPxAFYQRHesgn8c1AnqfCm43liYzp3jvX5mVRDyRsWuzcOzPR//a+x1RKVQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea026966001ex10-1_relmada.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT AGREEMENT, EFFECTIVE AS OF JANUARY 1, 2026, BETWEEN RELMADA THERAPEUTICS, INC. AND SERGIO TRAVERSA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">January 1, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sergio Traversa<BR>
650 NE 32 Street Unit 3804</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Miami, FL 33137</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Traversa:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Relmada Therapeutics, Inc.
(the &ldquo;<U>Company</U>&rdquo;) desires to continue to employ you and to have the benefit of your skills and services. The parties
entered into an Amended and Restated Employment Agreement on August 5, 2015 which is amended and restated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <U>Position</U>.
The terms of your position with the Company are as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) You
shall serve as Chief Executive Officer of the Company with such responsibilities, duties and authority as are assigned to you by the Company&rsquo;s
Board of Directors (the &ldquo;<U>Board</U>&rdquo;), or its designee. These responsibilities shall include implementation of the overall
direction of the Company as set by the Board, including, planning, corporate policies, research and development, staffing, finance and
operations. You shall perform such other duties and shall have authority consistent with your position as may be from time to time specified
by the Board and subject to the discretion of the Board. You shall report directly to the Board and shall perform your duties for the
Company at the Company&rsquo;s official place of business in Coral Gables, Florida except for travel that may be necessary or appropriate
in connection with the performance of your duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) You
agree to devote your best efforts and substantially all of your business time to advance the interests of the Company and to discharge
adequately your duties hereunder. You may hold up to two board seats on for-profit and not-for-profit boards that do not represent a conflict
with the Company and subject to Board approval after review of the time commitment involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.
<U>Effective Date</U>. The effective date of this agreement shall be January 1, 2025 (the &ldquo;Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.
<U>Proof of Right to Work</U>. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence
of your identity and eligibility for employment in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.
<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Base Salary</U>. You
will be paid an annual base salary of Eight Hundred Twenty-seven Thousand One Hundred Seventy-six dollars ($827,176), which will be paid
in accordance with the Company&rsquo;s regular payroll practices. The Board shall review the amount of your base salary and performance
bonus, and shall determine the appropriate adjustments to each component of your compensation within 60 days of the start of each calendar
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Performance
Cash Bonus</U>. You shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to
which the Board shall award bonuses to you, based upon the achievement of written individual and corporate objectives such as the Board
shall determine. Upon the attainment of such performance objectives, in addition to your base salary, you shall be entitled to a cash
bonus in an amount to be determined by the Board with a target of fifty percent (50%) of your base salary. Within thirty (30)&nbsp;days
after the Effective Date, the Board shall establish written individual and corporate performance objectives for the balance of 2020 and
the amount of the performance pro-rata bonus payable upon the attainment of each objective. At least thirty (30)&nbsp;days before each
subsequent calendar year, the Board shall establish written individual and corporate performance objectives for such calendar year and
the amount of the performance bonus payable upon the attainment of such objectives. Within sixty (60)&nbsp;days after the end of each
calendar year, the Board shall determine the amount of any performance bonus payable hereunder. Any such performance bonus shall be due
and payable within ninety (90)&nbsp;days after the end of the calendar year to which it relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) <U>Stock
Option and Restricted Stock Grants</U>. During the Term of this Agreement, you may also be awarded grants under the Company&rsquo;s 2021
Stock Option and Equity Incentive Plan, as amended, subject to board approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.
<U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Benefit
Plan &mdash; Health Insurance, Retirement and Stock Option Plan</U>. The Company will provide you with the opportunity to participate
in the standard benefits plans currently available to other similarly situated employees. The Company reserves the right to cancel and/or
change the benefits plans it offers to its employees at any time, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Vacation;
Sick Leave</U>. You will be entitled to 20 days paid vacation per year, pro-rated for the remainder of this calendar year and pro-rated
by the number of hours worked. Vacation may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per year
pro-rated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) <U>Other
Benefits</U>. The Company will provide you with standard business reimbursements (including mileage, supplies, long distance calls), subject
to Company policies and procedures and with appropriate receipts. In addition, you will receive any other statutory benefits required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(d) <U>Reimbursement
of Expenses</U>. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred
by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies in effect
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.  <U>Confidential
Information and Invention Assignment Agreement</U>. You have executed the Company&rsquo;s Confidential Information and Invention Assignment
Agreement, which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.
<U>At-Will Employment</U>. The initial term of your employment shall be a period of three (3)&nbsp;years from the Effective Date, provided
that your employment with the Company will be on an &ldquo;at will&rdquo; basis, meaning that either you or the Company may terminate
your employment at any time for any reason or no reason, without further obligation or liability, except as provided herein. In the event
that your employment is terminated because of your death or Disability, the Company&rsquo;s only obligation to you shall be to pay earned,
but unpaid, base salary (as of the date of termination) and provide you, if eligible, with the option to elect health coverage under the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;COBRA&rdquo;); provided that upon termination of your employment
hereunder due to death, your estate also shall be entitled to receive a single lump sum payment equal to three (3) months of your base
salary, payable within 30 days of your death. Upon termination of your employment for Cause (as defined below) you shall be paid any accrued
and unpaid base salary and benefits through the date of termination and shall have no further rights to any compensation or any other
benefits under the Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Termination
of Employment Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change in Control)</U>. If the Company terminates
your employment other than for Cause or if you resign for Good Reason, in any case in circumstances other than those described in Section
7(b), you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(i)  Subject
to Section 8 hereof, a single lump sum payment equal to twenty-four (24) months of your compensation (at the salary plus target bonus
rate in effect as of the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the
date of termination, on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(ii)  Subject
to Section 8 hereof, continued health benefits for the 24-month period beginning on the date of termination, with such period to run concurrently
with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing, you shall be required
to pay any and all employee premiums associated with continued health benefits and, if you become employed by another employer and become
covered by such employer&rsquo;s health benefits plan or program, the continued health benefits and cash payments provided hereunder shall
cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(iii) All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Change
in Control</U>. If the Company terminates your employment other than for Cause or if you resign for Good Reason, in any case during the
12-month period beginning on the date of a Change in Control (as defined in the 2014 Stock Option and Equity Incentive Plan, as amended),
you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(i) Subject
to Section 8 hereof, a single lump sum payment equal to thirty (30) months of your compensation (at the salary plus target bonus rate
in effect as of the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the date
of termination, on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable
in accordance with its terms.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(ii)  Subject
to Section 8 hereof, continued health benefits for the 30-month period beginning on the date of termination, with such period to run concurrently
with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing, you shall be required
to pay any and all employee premiums associated with continued health benefits and, if you become employed by another employer and become
covered by such employer&rsquo;s health benefits plan or program, the continued health benefits and cash payments provided hereunder shall
cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(iii) All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) &ldquo;<U>Cause</U>&rdquo;
means: that the Company has elected to terminate your employment with the Company because a majority of the members of the Company&rsquo;s
Board of Directors (the &ldquo;Board&rdquo;) has reasonably determined in good faith (after allowing you the opportunity to address the
alleged wrongdoing with the Board at a duly called meeting of the Board) that you have done any of the following: (i) failure by you to
perform your duties and responsibilities to the Company (or a Successor Company) or gross negligence or gross incompetence in the performance
of your duties, after written notice thereof and a failure to remedy such failure, if remediable, within sixty (60) days of such notice;
(ii) commission by you of any act of fraud, embezzlement, dishonesty or any other misconduct that has caused or is reasonably expected
to cause material injury to the Company (or a Successor Company, if appropriate), including commission of conduct constituting a felony
or crime involving fraud, moral turpitude or dishonesty; (iii) unauthorized use or disclosure by you of any confidential information of
the Company (or a Successor Company, if appropriate) or of any other party to whom you owe an obligation of nonuse and nondisclosure as
a result of your relationship with the Company (or a Successor Company, if appropriate); (iv) you engaging in conduct prohibited by the
Company (or Successor company, if appropriate) policy governing harassment and discrimination; (v) material breach by you of any of your
obligations under any written agreement with the Company (or a Successor Company, if appropriate) after written notice thereof and a failure
to remedy such breach, if remediable, within sixty (60) days of such notice; or (vi) breach of fiduciary duty. &ldquo;<U>Successor Company</U>&rdquo;
means the successor entity resulting from a Change of Control or a parent or subsidiary of such successor entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(d) &ldquo;<U>Good
Reason</U>&rdquo; means: (i) the Company&rsquo;s material breach of any of its obligations under this Agreement; (ii) a material reduction
by the Company of your base salary or target bonus opportunity; (iii) a material change to the title, scope of your work or employment
duties; (iv) a material adverse change in reporting relationship; (v) an abandonment of, or fundamental change in, the primary business
or primary products of the Company, or (vi) the Company&rsquo;s regular requirement that you perform services in or relocate to a location
that is more than fifty (50) miles from Coral Gables, Florida. A termination of employment will not be deemed to be for Good Reason unless
the Company does not cure within 30 days after receipt of written notice from you specifying the Good Reason and referring to your right
to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon your giving notice of your resignation for
Good Reason to the Company, conditioned upon your having provided proper notice of Good Reason and time to cure in accordance with this
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(e) &ldquo;<U>Disability</U>&rdquo;
shall mean that you are unable due to a physical or mental condition to perform the essential functions of his position with or without
reasonable accommodation for ninety (90) consecutive days or for one-hundred and eighty (180) days in the aggregate during any twelve
(12) month period or based on the written certification by a licensed physician of the likely continuation of such condition for either
such period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(f) <U>Mitigation</U>.
In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will not be
reduced for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment or benefit
under Sections 7(a)(i), 7(a)(ii), 7(b)(i) or 7(b)(ii) hereof unless: (a) you or your legal representative first executes within 45 calendar
days after the date of presentment, a release of claims agreement in the form as to be provided by the Company (the &ldquo;<U>Release</U>&rdquo;)
and substantially similar to the form of Release attached hereto as <U>Exhibit A</U>, (b) you do not revoke the Release, and (c) the Release
becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your review within ten
(10) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.  <U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of the Company&rsquo;s
employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either for yourself or any
other person or entity. For a period of 24 months following cessation of employment with the Company for any reason or no reason, you
shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from purchasing Company products or services
or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or
its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10. <U>Arbitration</U>. Any
dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of the Confidentiality
Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial Arbitration Rules of the American
Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the award rendered by the arbitrator may
be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences a transaction involving interstate
commerce and that the operation, interpretation and enforcement of this arbitration provision, the procedures to be used in conducting
an arbitration pursuant to this arbitration provision, and the confirmation of any award issued to either party by reason of such arbitration,
is governed exclusively by the Federal Arbitration Act, 9&nbsp;U.S.C. &sect;&nbsp;21 et&nbsp;seq. Notwithstanding the foregoing, the
parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance
with this paragraph, without breach of this arbitration provision. The Company shall pay all fees and expenses for the arbitration itself;
provided that the cost of the arbitrator will be equally divided between the parties. The Company will pay your legal fees, provided
that, if you substantially do not prevail, the Company shall be reimbursed for your reasonable legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11. <U>Indemnification</U>.
On August 5, 2015, you have entered into an Indemnification Agreement with the Company which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12. <U>Section
280G</U>. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid or
payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the &ldquo;<U>Total Payments</U>&rdquo;),
is or will be subject to the excise tax (the &ldquo;<U>Excise Tax</U>&rdquo;) imposed by Section 4999 of the Internal Revenue Code of
1986, as amended (the &ldquo;<U>Code</U>&rdquo;), then the Total Payments shall be reduced to the maximum amount that could be paid to
you without giving rise to the Excise Tax (the &ldquo;<U>Safe Harbor Cap</U>&rdquo;), if the net after-tax benefit to you after reducing
your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit to you without such reduction.
The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment that trigger the Excise Tax in the
following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of performance-based equity awards (based on
the reverse order of the date of grant), (iii) cancellation of accelerated vesting of other equity awards (based on the reverse order
of the date of grant), and (iv) reduction of any other payments due to you (with benefits or payments in any group having different payment
terms being reduced on a pro-rata basis). All mathematical determinations, and all determinations as to whether any of the Total Payments
are &ldquo;parachute payments&rdquo; (within the meaning of Section 280G of the Code), that are required to be made under this paragraph,
including determinations as to whether the Total Payments to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized
in arriving at such determinations, shall be made at the Company&rsquo;s expense by the Company&rsquo;s then current independent auditors,
or such other nationally recognized accounting firm selected by the Committee prior to the relevant change in control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13. <U>Section
409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>In
General</U>. It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements
of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or payments provided under this Agreement
are intended to be separate payments that qualify for the &ldquo;short-term deferral&rdquo; exception to Section 409A to the maximum extent
possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay exceptions to Section 409A,
to the maximum extent possible. If neither of these exceptions applies, and if you are a &ldquo;specified employee&rdquo; within the meaning
of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to the extent required to comply with Section
409A, all amounts that would otherwise be paid or provided to you during the first six (6) months following your date of termination shall
instead be accumulated through and paid or provided (without interest) on the first business day following the six-month anniversary of
the date of termination. If the period during which the Release must become effective and irrevocable in accordance with its terms spans
two calendar years, then, to the extent required to comply with Section 409A, any payment to be made under this Agreement will commence
on the first payroll date that occurs in the second calendar year and after the Release has become effective and irrevocable in accordance
with its terms. Further, to the extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you
may be entitled hereunder during a calendar year will not affect the amount of reimbursements to be provided in any other calendar year;
(ii) your right to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit;
and (iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before the last
day of the calendar year following the calendar year in which the expense was incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Separation
from Service</U>. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination
is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and the Participant is no longer providing services
(at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo; within the meaning of Section 409A) to the Company
or its Affiliates as an employee or consultant, and for purposes of any such provision of this Plan, references to a &ldquo;termination,&rdquo;
&ldquo;termination of employment&rdquo; or like terms shall mean &ldquo;separation from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14. <U>Attorneys&rsquo;
Fees.</U> Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to legal
proceedings in connection with this Agreement or Employee&rsquo;s employment with the Company, the party or parties prevailing in such
legal proceedings shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable attorneys&rsquo;
fees and costs in such legal proceedings from the non prevailing party or parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15. <U>Assistance
in Litigation</U>. Employee shall, during and after termination of employment, upon reasonable notice, furnish such information and proper
assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it or any of its subsidiaries
or affiliates is, or may become a party; provided, however, that such assistance following termination shall be furnished at mutually
agreeable times and for mutually agreeable compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16. <U>Miscellaneous</U>.
This Agreement, together with the Confidentiality Agreement, and Indemnification Agreement sets forth the terms of your employment with
the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended
except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will be lessened or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will
be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained
herein. This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i)&nbsp;on the date of delivery if delivered
personally, (ii)&nbsp;one (1)&nbsp;day after being sent by a well established commercial overnight service, (iii)&nbsp;three (3)&nbsp;days
after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors
at the following addresses, or at such other addresses as the parties may later designate in writing, (iv)&nbsp;upon confirmation of facsimile
transfer, if sent by facsimile or (v)&nbsp;upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2222 Ponce de Leon Blvd, Floor 3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coral Gables, FL 33134</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to you:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">650 NE 32 Street Unit 3804</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Miami, FL 33137</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17. <U>Withholding
of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company
is required to withhold pursuant to any law or government regulation or ruling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To indicate your acceptance
of this Agreement, please sign and date this letter in the space provided below and return it to me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED AND AGREED:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELMADA THERAPEUTICS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERGIO TRAVERSA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Charles Casamento&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%">/s/ Sergio Traversa&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles Casamento<BR>
Chairman of the Board</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;January 1, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;January 1, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RELEASE OF CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B>FOR AND IN CONSIDERATION
OF </B>the payments and benefits (the &ldquo;<B>Separation Benefits</B>&rdquo;) to be provided to me in connection with the separation
of my relationship with the Company, in accordance with the Agreement between Relmada Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;)
and me dated as August 5, 2015 (the &ldquo;<B>Agreement</B>&rdquo;), which Separation Benefits are conditioned on my signing this Release
of Claims (&ldquo;<B>Release</B>&rdquo;) and which I will forfeit unless I execute and do not revoke this Release of Claims, I, on my
own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the Company, its subsidiaries,
affiliates, parents, and stockholders, together with each of those entities&rsquo; respective officers, directors, stockholders, employees,
agents, fiduciaries and administrators (collectively, the &ldquo;<B>Releasees</B>&rdquo;) from any and all claims and rights of any nature
whatsoever which I now have against them up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This
Release includes, but is not limited to, any rights or claims relating in any way to my employment or consulting relationship with the
Company or any of the other Releasees or the termination thereof, any contract claims (express or implied, written or oral), including,
but not limited to, the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities
Act, the Age Discrimination in Employment Act, the Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including
Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil Rights Act
of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical
Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the
New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state
or local law. This Release specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive
and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee
benefits, or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of
race, color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality, mental
or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics), marital
status, military status, gender identity, harassment or any other basis prohibited by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of the Company
entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees, any complaints,
claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that I have not transferred
to any other person any such complaints, claims or lawsuits. I understand that by signing this Release, I waive my right to any monetary
recovery in connection with a local, state or federal governmental agency proceeding and I waive my right to file a claim seeking monetary
damages in any arbitral tribunal, administrative agency, or court. This Release does not: (i) prohibit or restrict me from communicating,
providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental
authority with responsibility for the administration of fair employment practices laws regarding a possible violation of such laws or
responding to any inquiry from such authority, including an inquiry about the existence of this Release or its underlying facts, or (ii)
require me to notify the Company of such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not
include and will not preclude: (a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights
under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&ldquo;<B>COBRA</B>&rdquo;); (c) claims for unemployment compensation;
(d) rights to defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my
employment with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted
by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company are
held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment, and/or (g)
any actions to enforce the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing herein shall be construed
to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required by legal process;
or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company before engaging in such communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I acknowledge that, in signing
this Release, I have not relied on any promises or representations, express or implied, other than those that are set forth expressly
herein or in the Agreement and that are intended to survive separation from employment, in accordance with the terms of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I further acknowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
first received this Release on the date of the Agreement to which it is attached as Exhibit A;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the
Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within 45 days of its presentation
to me after my Termination of Employment;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have carefully read and understand this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand that this Release is <B>LEGALLY BINDING </B>and by signing it I give up certain rights;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against
the Company and the Releasees, and I <B>KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE </B>the Company and the Releasees from any and all
claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition
to any benefit I would have otherwise received if I did not sign this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective
or enforceable until the seven (7) day revocation period has expired;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Release includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS </B>I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C.
&sect;621 <I>et seq.</I>); and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign
it, provided that I do not exercise my right to revoke this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intending to be legally bound, I have signed this Release as of the
date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: __________________________</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Signed: _____________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-3</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea026966001ex10-2_relmada.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT AGREEMENT, EFFECTIVE AS OF JANUARY 1, 2026, BETWEEN RELMADA THERAPEUTICS, INC. AND PAUL KELLY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">January 1, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Kelly<BR>
122 Sevilla Avenue PH 14,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coral Gables, FL 33134&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Kelly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Relmada Therapeutics, Inc: (the </FONT>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</FONT>&rdquo;),
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I am pleased to offer you the position of Chief Operating Officer.
Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward
to your future success in this position. The terms of your employment are set herein </FONT>(&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
Letter</FONT>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <U>Position</U>.
The terms of your position with the Company are as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) You
shall serve as Chief Operating Officer of the Company with such responsibilities duties and authority as are assigned to you by the Chief
Executive Officer (CEO) or designee. You shall report directly to the CEO. You shall perform your duties for the Company at a location
based on the needs of the Company as agreed with the CEO and you shall be available for any travel that may be necessary or appropriate
in connection with the performance of your duties hereunder. The headquarters of the Company is located in Coral Gables, Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) You
shall faithfully devote his full business/working time, attention and energy to the business and affairs of the Company and the performance
of his duties, which may be modified periodically by the CEO and to use his best efforts to perform such responsibilities faithfully and
efficiently. Without limiting the generality of the foregoing paragraph, the employee may join professional associations and otherwise
be involved with any other business activities, to the extent that, in the reasonable judgment of the CEO, such other business pursuits
and activities do not (i) interfere in any material respect with your ability to discharge Employee</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">s
duties and responsibilities to the Company, whether or not such activity is pursued for gain, profit or other pecuniary advantage, or
(ii) violate the Conflicts provision of Employee</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">s
Non-Disclosure Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.
<U>Effective Date</U>. The effective date of this agreement shall be January 1, 2025 (the &ldquo;Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.
<U>Proof of Right to Work</U>. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence
of your identity and eligibility for employment in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.
<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Base
Salary</U>. You will be paid an annual base salary of Five Hundred Twenty-four Thousand Seven Hundred Ninety dollars ($524,790), which
will be paid in accordance with the Company&rsquo;s regular payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Performance
Cash Bonus</U>. You shall be entitled to participate in a bonus program, which shall be established by the Board pursuant to which the
Board shall award bonuses to you, based upon the achievement of written individual and corporate objectives such as the CEO or Board shall
determine. Upon the attainment of such performance objectives, in addition to your base salary, you shall be entitled to a cash bonus
in an amount to be determined by the Board with a target of forty percent (40%) of your base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) <U>Stock
Option and Restricted Stock Grants</U>. During the Term of this Agreement, you may also be awarded grants under the Company&rsquo;s 2021
Stock Option and Equity Incentive Plan, as amended, subject to Board approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.
<U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Benefit
Plan &mdash; Health Insurance, Retirement and Stock Option Plan</U>. The Company will provide you with the opportunity to participate
in the standard benefits plans currently available to other similarly situated employees. The Company reserves the right to cancel and/or
change the benefits plans it offers to its employees at any time, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Vacation;
Sick Leave</U>. You will be entitled to 20 days paid vacation per year, pro-rated for the remainder of this calendar year and pro-rated
by the number of hours worked. Vacation may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per year
pro-rated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) <U>Other
Benefits</U>. The Company will provide you with standard business reimbursements (including mileage, supplies, long distance calls), subject
to Company policies and procedures and with appropriate receipts. In addition, you will receive any other statutory benefits required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(d) <U>Reimbursement
of Expenses</U>. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred
by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies in effect
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.  <U>Confidential
Information and Invention Assignment Agreement</U>. You have executed the Company&rsquo;s Confidential Information and Invention Assignment
Agreement, which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>At-Will Employment</U>. Your<SUP>.</SUP> employment with the Company will be on an </FONT>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
will</FONT>&rdquo; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">basis meaning that either you or the Company
may terminate your employment at any time for any reason or no reason, upon written notification to the other party, without further obligation
or liability, except as provided herein. In the event that your employment is terminated because of your death or Disability, the Company&rsquo;s
only obligation to you shall be to pay earned, but unpaid, base salary (as of the date of termination) and provide you, if eligible, with
the option to elect health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;COBRA&rdquo;);
provided that upon termination of your employment hereunder due to death, your estate also shall be entitled to receive a single lump
sum payment equal to three (3) months of your base salary, payable within 30 days of your death. Upon termination of your employment for
Cause (as defined below) you shall be paid any accrued and unpaid base salary and benefits through the date of termination and shall have
no further rights to any compensation or any other benefits under the Agreement or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) <U>Termination
of Employment Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change in Control)</U>. If the Company terminates
your employment other than for Cause or if you resign for Good Reason, in any case in circumstances other than those described in Section
7(b), you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; text-align: justify">(i)  Subject
to Section 8 hereof, a single lump sum payment equal to twelve (12) months of your compensation (at the salary plus target bonus rate
in effect as of the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the date
of termination, on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; text-align: justify">(ii)  Subject
to Section 8 hereof, continued health benefits for the 12-month period beginning on the date of termination, with such period to run concurrently
with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing, you shall be required
to pay any and all employee premiums associated with continued health benefits and, if you become employed by another employer and become
covered by such employer&rsquo;s health benefits plan or program, the continued health benefits and cash payments provided hereunder shall
cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; text-align: justify">(iii) All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>Change
in Control</U>. If the Company terminates your employment other than for Cause or if you resign for Good Reason, in any case during the
12-month period beginning on the date of a Change in Control (as defined in the 2021 Stock Option and Equity Incentive Plan, as amended),
you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; text-align: justify">(i) &nbsp;Subject
to Section 8 hereof, a single lump sum payment equal to eighteen (18) months of your compensation (at the salary plus target bonus rate
in effect as of the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the date
of termination, on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; text-align: justify">(ii)  Subject
to Section 8 hereof, continued health benefits for the 12-month period beginning on the date of termination, with such period to run concurrently
with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing, you shall be required
to pay any and all employee premiums associated with continued health benefits and, if you become employed by another employer and become
covered by such employer&rsquo;s health benefits plan or program, the continued health benefits and cash payments provided hereunder shall
cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; text-align: justify">(iii) All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &ldquo;<U>Cause</U>&rdquo;
means: that the Company has elected to terminate your employment with the Company because a majority of the members of the Company&rsquo;s
Board of Directors (the &ldquo;Board&rdquo;) has reasonably determined in good faith (after allowing you the opportunity to address the
alleged wrongdoing with the Board at a duly called meeting of the Board) that you have done any of the following: (i) failure by you to
perform your duties and responsibilities to the Company (or a Successor Company) or gross negligence or gross incompetence in the performance
of your duties, after written notice thereof and a failure to remedy such failure, if remediable, within sixty (60) days of such notice;
(ii) commission by you of any act of fraud, embezzlement, dishonesty or any other misconduct that has caused or is reasonably expected
to cause material injury to the Company (or a Successor Company, if appropriate), including commission of conduct constituting a felony
or crime involving fraud, moral turpitude or dishonesty; (iii) unauthorized use or disclosure by you of any confidential information of
the Company (or a Successor Company, if appropriate) or of any other party to whom you owe an obligation of nonuse and nondisclosure as
a result of your relationship with the Company (or a Successor Company, if appropriate); (iv) you engaging in conduct prohibited by the
Company (or Successor company, if appropriate) policy governing harassment and discrimination; (v) material breach by you of any of your
obligations under any written agreement with the Company (or a Successor Company, if appropriate) after written notice thereof and a failure
to remedy such breach, if remediable, within sixty (60) days of such notice; or (vi) breach of fiduciary duty. &ldquo;<U>Successor Company</U>&rdquo;
means the successor entity resulting from a Change of Control or a parent or subsidiary of such successor entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &ldquo;<U>Good
Reason</U>&rdquo; means: (i) the Company&rsquo;s material breach of any of its obligations under this Agreement; (ii) a material reduction
by the Company of your base salary or target bonus opportunity; (iii) a material change to the title, scope of your work or employment
duties; (iv) a material adverse change in reporting relationship; (v) an abandonment of, or fundamental change in, the primary business
or primary products of the Company, or (vi) the Company&rsquo;s regular requirement that you perform services in or relocate to a location
that is more than fifty (50) miles from Coral Gables, Florida. A termination of employment will not be deemed to be for Good Reason unless
the Company does not cure within 30 days after receipt of written notice from you specifying the Good Reason and referring to your right
to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon your giving notice of your resignation for
Good Reason to the Company, conditioned upon your having provided proper notice of Good Reason and time to cure in accordance with this
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &ldquo;<U>Disability</U>&rdquo;
shall mean that you are unable due to a physical or mental condition to perform the essential functions of his position with or without
reasonable accommodation for ninety (90) consecutive days or for one-hundred and eighty (180) days in the aggregate during any twelve
(12) month period or based on the written certification by a licensed physician of the likely continuation of such condition for either
such period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) <U>Mitigation</U>.
In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will not be
reduced for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment or benefit
under Sections 7(a)(i), 7(a)(ii), 7(b)(i) or 7(b)(ii) hereof unless: (a) you or your legal representative first executes within 45 calendar
days after the date of presentment, a release of claims agreement in the form as to be provided by the Company (the &ldquo;<U>Release</U>&rdquo;)
and substantially similar to the form of Release attached hereto as <U>Exhibit A</U>, (b) you do not revoke the Release, and (c) the Release
becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your review within ten
(10) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.  <U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of the Company&rsquo;s
employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either for yourself or any
other person or entity. For a period of 24 months following cessation of employment with the Company for any reason or no reason, you
shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from purchasing Company products or services
or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or
its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10. <U>Arbitration</U>.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of the
Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial Arbitration
Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the award rendered
by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences a transaction
involving interstate commerce and that the operation, interpretation and enforcement of this arbitration provision, the procedures to
be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of any award issued to either party
by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9&nbsp;U.S.C. &sect;&nbsp;21 et&nbsp;seq. Notwithstanding
the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel
arbitration in accordance with this paragraph, without breach of this arbitration provision. The Company shall pay all fees and expenses
for the arbitration itself; provided that the cost of the arbitrator will be equally divided between the parties. The Company will pay
your legal fees, provided that, if you substantially do not prevail, the Company shall be reimbursed for your reasonable legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11. <U>Indemnification</U>.
On August 5, 2015, you have entered into an Indemnification Agreement with the Company which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12. <U>Section
280G</U>. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid or
payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the &ldquo;<U>Total Payments</U>&rdquo;),
is or will be subject to the excise tax (the &ldquo;<U>Excise Tax</U>&rdquo;) imposed by Section 4999 of the Internal Revenue Code of
1986, as amended (the &ldquo;<U>Code</U>&rdquo;), then the Total Payments shall be reduced to the maximum amount that could be paid to
you without giving rise to the Excise Tax (the &ldquo;<U>Safe Harbor Cap</U>&rdquo;), if the net after-tax benefit to you after reducing
your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit to you without such reduction.
The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment that trigger the Excise Tax in the
following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of performance-based equity awards (based on
the reverse order of the date of grant), (iii) cancellation of accelerated vesting of other equity awards (based on the reverse order
of the date of grant), and (iv) reduction of any other payments due to you (with benefits or payments in any group having different payment
terms being reduced on a pro-rata basis). All mathematical determinations, and all determinations as to whether any of the Total Payments
are &ldquo;parachute payments&rdquo; (within the meaning of Section 280G of the Code), that are required to be made under this paragraph,
including determinations as to whether the Total Payments to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized
in arriving at such determinations, shall be made at the Company&rsquo;s expense by the Company&rsquo;s then current independent auditors,
or such other nationally recognized accounting firm selected by the Committee prior to the relevant change in control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13. <U>Section
409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>In
General</U>. It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements
of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or payments provided under this Agreement
are intended to be separate payments that qualify for the &ldquo;short-term deferral&rdquo; exception to Section 409A to the maximum extent
possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay exceptions to Section 409A,
to the maximum extent possible. If neither of these exceptions applies, and if you are a &ldquo;specified employee&rdquo; within the meaning
of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to the extent required to comply with Section
409A, all amounts that would otherwise be paid or provided to you during the first six (6) months following your date of termination shall
instead be accumulated through and paid or provided (without interest) on the first business day following the six-month anniversary of
the date of termination. If the period during which the Release must become effective and irrevocable in accordance with its terms spans
two calendar years, then, to the extent required to comply with Section 409A, any payment to be made under this Agreement will commence
on the first payroll date that occurs in the second calendar year and after the Release has become effective and irrevocable in accordance
with its terms. Further, to the extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you
may be entitled hereunder during a calendar year will not affect the amount of reimbursements to be provided in any other calendar year;
(ii) your right to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit;
and (iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before the last
day of the calendar year following the calendar year in which the expense was incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Separation
from Service</U>. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination
is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and the Participant is no longer providing services
(at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo; within the meaning of Section 409A) to the Company
or its Affiliates as an employee or consultant, and for purposes of any such provision of this Plan, references to a &ldquo;termination,&rdquo;
&ldquo;termination of employment&rdquo; or like terms shall mean &ldquo;separation from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14. <U>Attorneys&rsquo;
Fees.</U> Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to legal
proceedings in connection with this Agreement or Employee&rsquo;s employment with the Company, the party or parties prevailing in such
legal proceedings shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable attorneys&rsquo;
fees and costs in such legal proceedings from the non prevailing party or parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15. <U>Assistance
in Litigation</U>. Employee shall, during and after termination of employment, upon reasonable notice, furnish such information and proper
assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it or any of its subsidiaries
or affiliates is, or may become a party; provided, however, that such assistance following termination shall be furnished at mutually
agreeable times and for mutually agreeable compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16. <U>Miscellaneous</U>.
This Agreement, together with the Confidentiality Agreement, and Indemnification Agreement sets forth the terms of your employment with
the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended
except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will be lessened or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will
be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained
herein. This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i)&nbsp;on the date of delivery if delivered
personally, (ii)&nbsp;one (1)&nbsp;day after being sent by a well established commercial overnight service, (iii)&nbsp;three (3)&nbsp;days
after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors
at the following addresses, or at such other addresses as the parties may later designate in writing, (iv)&nbsp;upon confirmation of facsimile
transfer, if sent by facsimile or (v)&nbsp;upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2222 Ponce de Leon Blvd, Floor 3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coral Gables, FL 33134</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to you:</FONT></TD>
    <TD STYLE="width: 60%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">122 Sevilla Avenue PH 14,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coral Gables, FL 33134&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17. <U>Withholding
of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company
is required to withhold pursuant to any law or government regulation or ruling.</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To indicate your acceptance
of this Agreement, please sign and date this letter in the space provided below and return it to me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED AND AGREED:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELMADA THERAPEUTICS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAUL KELLY</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sergio Traversa</FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul Kelly</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sergio Traversa<BR>
Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;January 1, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;January 1, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RELEASE OF CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B>FOR AND IN CONSIDERATION
OF </B>the payments and benefits (the &ldquo;<B>Separation Benefits</B>&rdquo;) to be provided to me in connection with the separation
of my relationship with the Company, in accordance with the Agreement between Relmada Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;)
and me dated as August 5, 2015 (the &ldquo;<B>Agreement</B>&rdquo;), which Separation Benefits are conditioned on my signing this Release
of Claims (&ldquo;<B>Release</B>&rdquo;) and which I will forfeit unless I execute and do not revoke this Release of Claims, I, on my
own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the Company, its subsidiaries,
affiliates, parents, and stockholders, together with each of those entities&rsquo; respective officers, directors, stockholders, employees,
agents, fiduciaries and administrators (collectively, the &ldquo;<B>Releasees</B>&rdquo;) from any and all claims and rights of any nature
whatsoever which I now have against them up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This
Release includes, but is not limited to, any rights or claims relating in any way to my employment or consulting relationship with the
Company or any of the other Releasees or the termination thereof, any contract claims (express or implied, written or oral), including,
but not limited to, the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities
Act, the Age Discrimination in Employment Act, the Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including
Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil Rights Act
of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical
Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the
New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state
or local law. This Release specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive
and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee
benefits, or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of
race, color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality, mental
or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics), marital
status, military status, gender identity, harassment or any other basis prohibited by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of the Company
entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees, any complaints,
claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that I have not transferred
to any other person any such complaints, claims or lawsuits. I understand that by signing this Release, I waive my right to any monetary
recovery in connection with a local, state or federal governmental agency proceeding and I waive my right to file a claim seeking monetary
damages in any arbitral tribunal, administrative agency, or court. This Release does not: (i) prohibit or restrict me from communicating,
providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental
authority with responsibility for the administration of fair employment practices laws regarding a possible violation of such laws or
responding to any inquiry from such authority, including an inquiry about the existence of this Release or its underlying facts, or (ii)
require me to notify the Company of such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not
include and will not preclude: (a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights
under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&ldquo;<B>COBRA</B>&rdquo;); (c) claims for unemployment compensation;
(d) rights to defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my
employment with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted
by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company are
held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment, and/or (g)
any actions to enforce the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing herein shall be construed
to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required by legal process;
or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company before engaging in such communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I acknowledge that, in signing
this Release, I have not relied on any promises or representations, express or implied, other than those that are set forth expressly
herein or in the Agreement and that are intended to survive separation from employment, in accordance with the terms of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I further acknowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I first received this Release on the date of the Agreement to which it is attached as Exhibit A;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within 45 days of its presentation to me after my Termination of Employment;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have carefully read and understand this Release;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I understand that this Release is <B>LEGALLY BINDING </B>and by signing it I give up certain rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against the Company and the Releasees, and I <B>KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE </B>the Company and the Releasees from any and all claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition to any benefit I would have otherwise received if I did not sign this Release;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective or enforceable until the seven (7) day revocation period has expired;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Release includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS </B>I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C. &sect;621 <I>et seq.</I>); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign it, provided that I do not exercise my right to revoke this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intending to be legally bound, I have signed this Release as of the
date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 59%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: __________________________</FONT></TD>
    <TD STYLE="width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Signed: _____________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ea026966001ex10-3_relmada.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT AGREEMENT, EFFECTIVE AS OF JANUARY 1, 2026, BETWEEN RELMADA THERAPEUTICS, INC. AND MAGED SHENOUDA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">January 1, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maged Shenouda<BR>
9 James Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Montclair, NJ 07042</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Shenouda:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On behalf of Relmada Therapeutics, Inc: (the &ldquo;Company&rdquo;),
I am pleased to offer you the position of Chief Financial Officer. Speaking for myself, as well as the other members of the Board of Directors,
we are all impressed with your credentials and look forward to your future success in this position. The terms of your employment are
set herein (&ldquo;Employment Letter&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <U>Position</U>.
The terms of your position with the Company are as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) You
shall serve as Chief Financial Officer of the Company with such responsibilities duties and authority as are assigned to you by the Chief
Executive Officer (CEO). You shall report directly to the CEO. You shall perform your duties for the Company at the Company&rsquo;s offices,
except as otherwise agreed with the CEO and for travel that may be necessary or appropriate in connection with the performance of your
duties hereunder. The headquarters of the Company is located in Coral Gables, Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) You
shall faithfully devote his full business/working time, attention and energy to the business and affairs of the Company and the performance
of his duties, which may be modified periodically by the CEO and to use his best efforts to perform such responsibilities faithfully and
efficiently. Without limiting the generality of the foregoing paragraph, the employee may join professional associations and otherwise
be involved with any other business activities, to the extent that, in the reasonable judgment of the CEO, such other business pursuits
and activities do not (i) interfere in any material respect with your ability to discharge Employee&rsquo;s duties and responsibilities to the
Company, whether or not such activity is pursued for gain, profit or other pecuniary advantage, or (ii) violate the Conflicts provision
of Employee&rsquo;s Non-Disclosure Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.
<U>Effective Date</U>. The effective date of this agreement shall be January 1, 2025 (the &ldquo;Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.
<U>Proof of Right to Work</U>. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence
of your identity and eligibility for employment in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.
<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Base Salary</U>. You
will be paid an annual base salary of Five Hundred Eighty-Six Thousand Nine Hundred Forty dollars ($586,940), which will be paid in accordance
with the Company&rsquo;s regular payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Performance
Cash Bonus</U>. You shall be entitled to participate in a bonus program, which shall be established by the Board pursuant to which the
Board shall award bonuses to you, based upon the achievement of written individual and corporate objectives such as the CEO or Board shall
determine. Upon the attainment of such performance objectives, in addition to your base salary, you shall be entitled to a cash bonus
in an amount to be determined by the Board with a target of forty percent (40%) of your base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) <U>Stock
Option and Restricted Stock Grants</U>. During the Term of this Agreement, you may also be awarded grants under the Company&rsquo;s 2021
Stock Option and Equity Incentive Plan, as amended (the &ldquo;Stock Plan&rdquo;), subject to Board approval. For the avoidance of doubt,
your options granted to you as a Director of the Company shall continue to vest in accordance with the terms of the Stock Plan, so long
as you remain employed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.
<U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Benefit
Plan &mdash; Health Insurance, Retirement and Stock Option Plan</U>. The Company will provide you with the opportunity to participate
in the standard benefits plans currently available to other similarly situated employees. The Company reserves the right to cancel and/or
change the benefits plans it offers to its employees at any time, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Vacation;
Sick Leave</U>. You will be entitled to 20 days paid vacation per year, pro-rated for the remainder of this calendar year and pro-rated
by the number of hours worked. Vacation may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per year
pro-rated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) <U>Other
Benefits</U>. The Company will provide you with standard business reimbursements (including mileage, supplies, long distance calls), subject
to Company policies and procedures and with appropriate receipts. In addition, you will receive any other statutory benefits required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(d) <U>Reimbursement
of Expenses</U>. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred
by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies in effect
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.  <U>Confidential
Information and Invention Assignment Agreement</U>. You have executed the Company&rsquo;s Confidential Information and Invention Assignment
Agreement, which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.
<U>At-Will Employment</U>. Your<SUP>.</SUP> employment with the Company will be on an &ldquo;at will&rdquo; basis meaning that either you
or the Company may terminate your employment at any time for any reason or no reason, upon written notification to the other party, without
further obligation or liability, except as provided herein. In the event that your employment is terminated because of your death or Disability,
the Company&rsquo;s only obligation to you shall be to pay earned, but unpaid, base salary (as of the date of termination) and provide
you, if eligible, with the option to elect health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(&ldquo;COBRA&rdquo;); provided that upon termination of your employment hereunder due to death, your estate also shall be entitled to
receive a single lump sum payment equal to three (3) months of your base salary, payable within 30 days of your death. Upon termination
of your employment for Cause (as defined below) you shall be paid any accrued and unpaid base salary and benefits through the date of
termination and shall have no further rights to any compensation or any other benefits under the Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Termination
of Employment Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change in Control)</U>. If the Company terminates
your employment other than for Cause or if you resign for Good Reason, in any case in circumstances other than those described in Section
7(b), you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(i)  Subject
to Section 8 hereof, a single lump sum payment equal to twelve (12) months of your compensation (at the salary plus target bonus rate in effect
as of the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the date of termination,
on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable in accordance
with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(ii)  Subject
to Section 8 hereof, following the termination of your employment, the Company will provide you with continued health insurance coverage
for the longer of (i) twelve (12) months following your termination date or (ii) when you become eligible for Medicare coverage (Part
A or Part B) and are at least 65 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Such coverage shall be substantially
equivalent in scope and cost to the coverage you received as an active employee.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&rsquo;s obligation under
this Section shall not be limited by the duration of COBRA continuation coverage. You shall pay the employee portion of premiums at the
same rate applicable to active employees, and the Company shall pay the employer portion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">To the extent COBRA continuation coverage
is available, this contractual coverage shall run concurrently with COBRA. If COBRA expires before the end of the required coverage period,
the Company will obtain and maintain substitute individual or group health coverage that is substantially equivalent to the Company&rsquo;s
then-current medical plan through the earlier of (i) the date you become eligible for other employer-sponsored health coverage or (ii)
the date you have both become eligible for Medicare coverage (Part A and Part B) and are at least 65 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(iii) All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Change
in Control</U>. If the Company terminates your employment other than for Cause or if you resign for Good Reason, in any case during the
12-month period beginning on the date of a Change in Control (as defined in the 2021 Stock Option and Equity Incentive Plan, as amended),
you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(i) &nbsp;Subject
to Section 8 hereof, a single lump sum payment equal to eighteen (18) months of your compensation (at the salary plus target bonus rate in effect
as of the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the date of termination,
on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable in accordance
with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(ii)  Subject
to Section 8 hereof, following the termination of your employment, the Company will provide you with continued health insurance coverage
for the longer of (i) twelve (12) months following your termination date or (ii) when you become eligible for Medicare coverage (Part
A or Part B) and are at least 65 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Such coverage shall be substantially
equivalent in scope and cost to the coverage you received as an active employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&rsquo;s obligation under
this Section shall not be limited by the duration of COBRA continuation coverage. You shall pay the employee portion of premiums at the
same rate applicable to active employees, and the Company shall pay the employer portion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">To the extent COBRA continuation coverage
is available, this contractual coverage shall run concurrently with COBRA. If COBRA expires before the end of the required coverage period,
the Company will obtain and maintain substitute individual or group health coverage that is substantially equivalent to the Company&rsquo;s
then-current medical plan through the earlier of (i) the date you become eligible for other employer-sponsored health coverage or (ii)
the date you have both become eligible for Medicare coverage (Part A and Part B) and are at least 65 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(iii) All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c) &ldquo;<U>Cause</U>&rdquo;
means: that the Company has elected to terminate your employment with the Company because a majority of the members of the Company&rsquo;s
Board of Directors (the &ldquo;Board&rdquo;) has reasonably determined in good faith (after allowing you the opportunity to address the
alleged wrongdoing with the Board at a duly called meeting of the Board) that you have done any of the following: (i) failure by you to
perform your duties and responsibilities to the Company (or a Successor Company) or gross negligence or gross incompetence in the performance
of your duties, after written notice thereof and a failure to remedy such failure, if remediable, within sixty (60) days of such notice;
(ii) commission by you of any act of fraud, embezzlement, dishonesty or any other misconduct that has caused or is reasonably expected
to cause material injury to the Company (or a Successor Company, if appropriate), including commission of conduct constituting a felony
or crime involving fraud, moral turpitude or dishonesty; (iii) unauthorized use or disclosure by you of any confidential information of
the Company (or a Successor Company, if appropriate) or of any other party to whom you owe an obligation of nonuse and nondisclosure as
a result of your relationship with the Company (or a Successor Company, if appropriate); (iv) if determined after an impartial investigation
that you engaging in conduct prohibited by the Company (or Successor company, if appropriate) policy governing harassment and discrimination;
(v) material breach by you of any of your obligations under any written agreement with the Company (or a Successor Company, if appropriate)
after written notice thereof and a failure to remedy such breach, if remediable, within sixty (60) days of such notice; or (vi) breach
of fiduciary duty. &ldquo;<U>Successor Company</U>&rdquo; means the successor entity resulting from a Change of Control or a parent or
subsidiary of such successor entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(d) &ldquo;<U>Good
Reason</U>&rdquo; means: (i) the Company&rsquo;s material breach of any of its obligations under this Agreement; (ii) a material reduction
by the Company of your base salary or target bonus opportunity; (iii) a material change to the title, scope of your work or employment
duties; (iv) a material adverse change in reporting relationship; (v) an abandonment of, or fundamental change in, the primary business
or primary products of the Company, or (vi) the Company&rsquo;s regular requirement that you perform services in or relocate to a location
that is more than fifty (50) miles from Coral Gables, Florida. A termination of employment will not be deemed to be for Good Reason unless
the Company does not cure within 30 days after receipt of written notice from you specifying the Good Reason and referring to your right
to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon your giving notice of your resignation for
Good Reason to the Company, conditioned upon your having provided proper notice of Good Reason and time to cure in accordance with this
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(e) &ldquo;<U>Disability</U>&rdquo;
shall mean that you are unable due to a physical or mental condition to perform the essential functions of his position with or without
reasonable accommodation for ninety (90) consecutive days or for one-hundred and eighty (180) days in the aggregate during any twelve
(12) month period or based on the written certification by a licensed physician of the likely continuation of such condition for either
such period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(f) <U>Mitigation</U>.
In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will not be
reduced for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment or benefit
under Sections 7(a)(i), 7(a)(ii), 7(b)(i) or 7(b)(ii) hereof unless: (a) you or your legal representative first executes within 45 calendar
days after the date of presentment, a release of claims agreement in the form as to be provided by the Company (the &ldquo;<U>Release</U>&rdquo;)
and substantially similar to the form of Release attached hereto as <U>Exhibit A</U>, (b) you do not revoke the Release, and (c) the Release
becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your review within ten
(10) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.  <U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of the Company&rsquo;s
employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either for yourself or any
other person or entity. For a period of 24 months following cessation of employment with the Company for any reason or no reason, you
shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from purchasing Company products or services
or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or
its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10. <U>Arbitration</U>.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of the
Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial
Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the
award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement
evidences a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration
provision, the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of
any award issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act,
9&nbsp;U.S.C. &sect;&nbsp;21 et&nbsp;seq. Notwithstanding the foregoing, the parties may apply to any court of competent
jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance with this paragraph, without breach
of this arbitration provision. The Company shall pay all fees and expenses for the arbitration itself, including the cost of the
arbitrator. Each party shall pay its own legal fees and costs in any legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11. <U>Indemnification</U>.
On August 5, 2015, you have entered into an Indemnification Agreement with the Company which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12. <U>Section
280G</U>. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid or
payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the &ldquo;<U>Total Payments</U>&rdquo;),
is or will be subject to the excise tax (the &ldquo;<U>Excise Tax</U>&rdquo;) imposed by Section 4999 of the Internal Revenue Code of
1986, as amended (the &ldquo;<U>Code</U>&rdquo;), then the Total Payments shall be reduced to the maximum amount that could be paid to
you without giving rise to the Excise Tax (the &ldquo;<U>Safe Harbor Cap</U>&rdquo;), if the net after-tax benefit to you after reducing
your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit to you without such reduction.
The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment that trigger the Excise Tax in the
following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of performance-based equity awards (based on
the reverse order of the date of grant), (iii) cancellation of accelerated vesting of other equity awards (based on the reverse order
of the date of grant), and (iv) reduction of any other payments due to you (with benefits or payments in any group having different payment
terms being reduced on a pro-rata basis). All mathematical determinations, and all determinations as to whether any of the Total Payments
are &ldquo;parachute payments&rdquo; (within the meaning of Section 280G of the Code), that are required to be made under this paragraph,
including determinations as to whether the Total Payments to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized
in arriving at such determinations, shall be made at the Company&rsquo;s expense by the Company&rsquo;s then current independent auditors,
or such other nationally recognized accounting firm selected by the Committee prior to the relevant change in control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13. <U>Section
409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>In
General</U>. It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements
of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or payments provided under this Agreement
are intended to be separate payments that qualify for the &ldquo;short-term deferral&rdquo; exception to Section 409A to the maximum extent
possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay exceptions to Section 409A,
to the maximum extent possible. If neither of these exceptions applies, and if you are a &ldquo;specified employee&rdquo; within the meaning
of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to the extent required to comply with Section
409A, all amounts that would otherwise be paid or provided to you during the first six (6) months following your date of termination shall
instead be accumulated through and paid or provided (without interest) on the first business day following the six-month anniversary of
the date of termination. If the period during which the Release must become effective and irrevocable in accordance with its terms spans
two calendar years, then, to the extent required to comply with Section 409A, any payment to be made under this Agreement will commence
on the first payroll date that occurs in the second calendar year and after the Release has become effective and irrevocable in accordance
with its terms. Further, to the extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you
may be entitled hereunder during a calendar year will not affect the amount of reimbursements to be provided in any other calendar year;
(ii) your right to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit;
and (iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before the last
day of the calendar year following the calendar year in which the expense was incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b) <U>Separation
from Service</U>. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination
is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and the Participant is no longer providing services
(at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo; within the meaning of Section 409A) to the Company
or its Affiliates as an employee or consultant, and for purposes of any such provision of this Plan, references to a &ldquo;termination,&rdquo;
&ldquo;termination of employment&rdquo; or like terms shall mean &ldquo;separation from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14. <U>Assistance
in Litigation</U>. Employee shall, during and after termination of employment, upon reasonable notice, furnish such information and proper
assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it or any of its subsidiaries
or affiliates is, or may become a party; provided, however, that such assistance following termination shall be furnished at mutually
agreeable times and for mutually agreeable compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15. <U>Miscellaneous</U>.
This Agreement, together with the Confidentiality Agreement, and Indemnification Agreement sets forth the terms of your employment with
the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended
except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will be lessened or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will
be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained
herein. This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i)&nbsp;on the date of delivery if delivered
personally, (ii)&nbsp;one (1)&nbsp;day after being sent by a well established commercial overnight service, (iii)&nbsp;three (3)&nbsp;days
after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors
at the following addresses, or at such other addresses as the parties may later designate in writing, (iv)&nbsp;upon confirmation of facsimile
transfer, if sent by facsimile or (v)&nbsp;upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2222 Ponce de Leon Blvd, Floor 3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coral Gables, FL 33134</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to you:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9 James Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Montclair, NJ 07042</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16. <U>Withholding
of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company
is required to withhold pursuant to any law or government regulation or ruling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To indicate your acceptance
of this Agreement, please sign and date this letter in the space provided below and return it to me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED AND AGREED:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELMADA THERAPEUTICS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MAGED SHENOUDA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%">/s/ Sergio Traversa</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%">/s/ Maged Shenouda</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sergio Traversa<BR>
Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;January 1, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;January 1, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RELEASE OF CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B>FOR AND IN CONSIDERATION
OF </B>the payments and benefits (the &ldquo;<B>Separation Benefits</B>&rdquo;) to be provided to me in connection with the separation
of my relationship with the Company, in accordance with the Agreement between Relmada Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;)
and me dated as August 5, 2015 (the &ldquo;<B>Agreement</B>&rdquo;), which Separation Benefits are conditioned on my signing this Release
of Claims (&ldquo;<B>Release</B>&rdquo;) and which I will forfeit unless I execute and do not revoke this Release of Claims, I, on my
own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the Company, its subsidiaries,
affiliates, parents, and stockholders, together with each of those entities&rsquo; respective officers, directors, stockholders, employees,
agents, fiduciaries and administrators (collectively, the &ldquo;<B>Releasees</B>&rdquo;) from any and all claims and rights of any nature
whatsoever which I now have against them up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This
Release includes, but is not limited to, any rights or claims relating in any way to my employment or consulting relationship with the
Company or any of the other Releasees or the termination thereof, any contract claims (express or implied, written or oral), including,
but not limited to, the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities
Act, the Age Discrimination in Employment Act, the Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including
Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil Rights Act
of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical
Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the
New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state
or local law. This Release specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive
and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee
benefits, or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of
race, color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality, mental
or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics), marital
status, military status, gender identity, harassment or any other basis prohibited by law. Notwithstanding the foregoing, this release
of claims against individual employees and stockholders is limited to claims based upon my employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of the Company
entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees, any complaints,
claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that I have not transferred
to any other person any such complaints, claims or lawsuits. I understand that by signing this Release, I waive my right to any monetary
recovery in connection with a local, state or federal governmental agency proceeding and I waive my right to file a claim seeking monetary
damages in any arbitral tribunal, administrative agency, or court. This Release does not: (i) prohibit or restrict me from communicating,
providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental
authority with responsibility for the administration of fair employment practices laws regarding a possible violation of such laws or
responding to any inquiry from such authority, including an inquiry about the existence of this Release or its underlying facts, or (ii)
require me to notify the Company of such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not
include and will not preclude: (a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights
under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&ldquo;<B>COBRA</B>&rdquo;); (c) claims for unemployment compensation;
(d) rights to defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my
employment with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted
by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company are
held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment, and/or (g)
any actions to enforce the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing herein shall be construed
to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required by legal process;
or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company before engaging in such communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I acknowledge that, in signing
this Release, I have not relied on any promises or representations, express or implied, other than those that are set forth expressly
herein or in the Agreement and that are intended to survive separation from employment, in accordance with the terms of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I further acknowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
first received this Release on the date of the Agreement to which it is attached as Exhibit A;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the
Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within 45 days of its presentation
to me after my Termination of Employment;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have carefully read and understand this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand that this Release is <B>LEGALLY BINDING </B>and by signing it I give up certain rights;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against
the Company and the Releasees, and I <B>KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE </B>the Company and the Releasees from any and all
claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition
to any benefit I would have otherwise received if I did not sign this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective
or enforceable until the seven (7) day revocation period has expired;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Release includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS </B>I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C.
&sect;621 <I>et seq.</I>); and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign
it, provided that I do not exercise my right to revoke this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intending to be legally bound, I have signed this Release as of the
date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: __________________________</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Signed: _____________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-3</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ea026966001ex10-4_relmada.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT AGREEMENT, EFFECTIVE AS OF JANUARY 1, 2025, BETWEEN RELMADA THERAPEUTICS, INC. AND CHARLES ENCE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.4</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">January 1, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Charles Ence<BR>
5861 S Albion Ct</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Greenwood Village, CO 80121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Ence:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On behalf of Relmada Therapeutics, Inc: (the &ldquo;Company&rdquo;),
I am pleased to offer you the position of Chief Accounting and Compliance Officer. Speaking for myself, as well as the other members of
the Board of Directors, we are all impressed with your credentials and look forward to your future success in this position. The terms
of your employment are set herein (&ldquo;Employment Letter&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.    <U>Position</U>.
The terms of your position with the Company are as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) You
shall serve as Chief Accounting and Compliance Officer of the Company with such responsibilities, duties and authority as are assigned
to you by the Chief Executive Officer (CEO) or designee. You shall report directly to the CEO. You shall perform your duties for the Company
at a location based on the needs of the Company as agreed with the CEO and you shall be available for any travel that may be necessary
or appropriate in connection with the performance of your duties hereunder. The headquarters of the Company is located in Coral Gables,
Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b)    You
shall faithfully devote his full business/working time, attention and energy to the business and affairs of the Company and the performance
of his duties, which may be modified periodically by the CEO and to use his best efforts to perform such responsibilities faithfully and
efficiently. Without limiting the generality of the foregoing paragraph, the employee may join professional associations and otherwise
be involved with any other business activities, to the extent that, in the reasonable judgment of the CEO, such other business pursuits
and activities do not (i) interfere in any material respect with your ability to discharge Employee&rsquo;s duties and responsibilities to the
Company, whether or not such activity is pursued for gain, profit or other pecuniary advantage, or (ii) violate the Conflicts provision
of Employee&rsquo;s Non-Disclosure Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.
<U>Effective Date</U>. The effective date of this agreement shall be January 1, 2025 (the &ldquo;Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.
<U>Proof of Right to Work</U>. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence
of your identity and eligibility for employment in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.
<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a) <U>Base
Salary</U>. You will be paid an annual base salary of Five Hundred seventy-six Thousand Four Hundred Forty dollars ($576,440), which
will be paid in accordance with the Company&rsquo;s regular payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b)    <U>Performance
Cash Bonus</U>. You shall be entitled to participate in a bonus program, which shall be established by the Board pursuant to which the
Board shall award bonuses to you, based upon the achievement of written individual and corporate objectives such as the CEO or Board shall
determine. Upon the attainment of such performance objectives, in addition to your base salary, you shall be entitled to a cash bonus
in an amount to be determined by the Board with a target of forty percent (40%) of your base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c)    <U>Stock
Option and Restricted Stock Grants</U>. During the Term of this Agreement, you may also be awarded grants under the Company&rsquo;s 2021
Stock Option and Equity Incentive Plan, as amended, subject to Board approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.
<U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a)    <U>Benefit
Plan &mdash; Health Insurance, Retirement and Stock Option Plan</U>. The Company will provide you with the opportunity to participate
in the standard benefits plans currently available to other similarly situated employees. The Company reserves the right to cancel and/or
change the benefits plans it offers to its employees at any time, subject to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b)    <U>Vacation;
Sick Leave</U>. You will be entitled to 20 days paid vacation per year, pro-rated for the remainder of this calendar year and pro-rated
by the number of hours worked. Vacation may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per year
pro-rated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c)    <U>Other
Benefits</U>. The Company will provide you with standard business reimbursements (including mileage, supplies, long distance calls), subject
to Company policies and procedures and with appropriate receipts. In addition, you will receive any other statutory benefits required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(d)    <U>Reimbursement
of Expenses</U>. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred
by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies in effect
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.     <U>Confidential
Information and Invention Assignment Agreement</U>. You have executed the Company&rsquo;s Confidential Information and Invention Assignment
Agreement, which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.
<U>At-Will Employment</U>. Your<SUP>.</SUP> employment with the Company will be on an &ldquo;at will&rdquo; basis meaning that either you
or the Company may terminate your employment at any time for any reason or no reason, upon written notification to the other party, without
further obligation or liability, except as provided herein. In the event that your employment is terminated because of your death or Disability,
the Company&rsquo;s only obligation to you shall be to pay earned, but unpaid, base salary (as of the date of termination) and provide
you, if eligible, with the option to elect health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(&ldquo;COBRA&rdquo;); provided that upon termination of your employment hereunder due to death, your estate also shall be entitled to
receive a single lump sum payment equal to three (3) months of your base salary, payable within 30 days of your death. Upon termination
of your employment for Cause (as defined below) you shall be paid any accrued and unpaid base salary and benefits through the date of
termination and shall have no further rights to any compensation or any other benefits under the Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a)    <U>Termination
of Employment Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change in Control)</U>. If the Company terminates
your employment other than for Cause or if you resign for Good Reason, in any case in circumstances other than those described in Section
7(b), you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)     Subject
to Section 8 hereof, a single lump sum payment equal to twelve (12) months of your compensation (at the salary plus target bonus rate in effect
as of the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the date of termination,
on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and irrevocable in accordance
with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)     Subject
to Section 8 hereof, continued health benefits for the 12-month period beginning on the date of termination, with such period to run concurrently
with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing, you shall be required
to pay any and all employee premiums associated with continued health benefits and, if you become employed by another employer and become
covered by such employer&rsquo;s health benefits plan or program, the continued health benefits and cash payments provided hereunder shall
cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)    All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b)    <U>Change
in Control</U>. If the Company terminates your employment other than for Cause or if you resign for Good Reason, in any case during the
12-month period beginning on the date of a Change in Control (as defined in the 2021 Stock Option and Equity Incentive Plan, as amended),
you shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i) Subject to Section 8 hereof,
a single lump sum payment equal to eighteen (18) months of your compensation (at the salary plus target bonus rate in effect as of
the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices in effect at the date of
termination, on the first payroll date following the date the Release (as defined in Section 8 hereof) becomes effective and
irrevocable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)     Subject
to Section 8 hereof, continued health benefits for the 12-month period beginning on the date of termination, with such period to run concurrently
with any period for which you are eligible to elect health coverage under COBRA. Notwithstanding the foregoing, you shall be required
to pay any and all employee premiums associated with continued health benefits and, if you become employed by another employer and become
covered by such employer&rsquo;s health benefits plan or program, the continued health benefits and cash payments provided hereunder shall
cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)    All
outstanding equity and long-term incentive awards granted to you under the Company&rsquo;s equity compensation plans shall become immediately
vested and exercisable through the term of the respective option and long-term incentive agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(c)    &ldquo;<U>Cause</U>&rdquo;
means: that the Company has elected to terminate your employment with the Company because a majority of the members of the Company&rsquo;s
Board of Directors (the &ldquo;Board&rdquo;) has reasonably determined in good faith (after allowing you the opportunity to address the
alleged wrongdoing with the Board at a duly called meeting of the Board) that you have done any of the following: (i) failure by you to
perform your duties and responsibilities to the Company (or a Successor Company) or gross negligence or gross incompetence in the performance
of your duties, after written notice thereof and a failure to remedy such failure, if remediable, within sixty (60) days of such notice;
(ii) commission by you of any act of fraud, embezzlement, dishonesty or any other misconduct that has caused or is reasonably expected
to cause material injury to the Company (or a Successor Company, if appropriate), including commission of conduct constituting a felony
or crime involving fraud, moral turpitude or dishonesty; (iii) unauthorized use or disclosure by you of any confidential information of
the Company (or a Successor Company, if appropriate) or of any other party to whom you owe an obligation of nonuse and nondisclosure as
a result of your relationship with the Company (or a Successor Company, if appropriate); (iv) you engaging in conduct prohibited by the
Company (or Successor company, if appropriate) policy governing harassment and discrimination; (v) material breach by you of any of your
obligations under any written agreement with the Company (or a Successor Company, if appropriate) after written notice thereof and a failure
to remedy such breach, if remediable, within sixty (60) days of such notice; or (vi) breach of fiduciary duty. &ldquo;<U>Successor Company</U>&rdquo;
means the successor entity resulting from a Change of Control or a parent or subsidiary of such successor entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(d)    &ldquo;<U>Good
Reason</U>&rdquo; means: (i) the Company&rsquo;s material breach of any of its obligations under this Agreement; (ii) a material reduction
by the Company of your base salary or target bonus opportunity; (iii) a material change to the title, scope of your work or employment
duties; (iv) a material adverse change in reporting relationship; (v) an abandonment of, or fundamental change in, the primary business
or primary products of the Company, or (vi) the Company&rsquo;s regular requirement that you perform services in or relocate to a location
that is more than fifty (50) miles from Coral Gables, Florida. A termination of employment will not be deemed to be for Good Reason unless
the Company does not cure within 30 days after receipt of written notice from you specifying the Good Reason and referring to your right
to resign for Good Reason. Any resignation for Good Reason will be effective immediately upon your giving notice of your resignation for
Good Reason to the Company, conditioned upon your having provided proper notice of Good Reason and time to cure in accordance with this
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(e)    &ldquo;<U>Disability</U>&rdquo;
shall mean that you are unable due to a physical or mental condition to perform the essential functions of his position with or without
reasonable accommodation for ninety (90) consecutive days or for one-hundred and eighty (180) days in the aggregate during any twelve
(12) month period or based on the written certification by a licensed physician of the likely continuation of such condition for either
such period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(f)    <U>Mitigation</U>.
In the event that you are entitled to severance pursuant to this Agreement, you have no duty to mitigate and your severance will not be
reduced for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.    <U>Release</U>.
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to provide any severance payment or benefit
under Sections 7(a)(i), 7(a)(ii), 7(b)(i) or 7(b)(ii) hereof unless: (a) you or your legal representative first executes within 45 calendar
days after the date of presentment, a release of claims agreement in the form as to be provided by the Company (the &ldquo;<U>Release</U>&rdquo;)
and substantially similar to the form of Release attached hereto as <U>Exhibit A</U>, (b) you do not revoke the Release, and (c) the Release
becomes effective and irrevocable in accordance with its terms. The Company shall provide the Release to you for your review within ten
(10) days of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.     <U>Non-Solicitation</U>.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of the Company&rsquo;s
employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either for yourself or any
other person or entity. For a period of 24 months following cessation of employment with the Company for any reason or no reason, you
shall not attempt to negatively influence any of the Company&rsquo;s clients or customers from purchasing Company products or services
or to solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or
its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.
<U>Arbitration</U>. Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to
enforcement of the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial
Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the award
rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences a
transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration provision, the procedures
to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of any award issued to either party
by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9&nbsp;U.S.C. &sect;&nbsp;21 et&nbsp;seq. Notwithstanding
the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel
arbitration in accordance with this paragraph, without breach of this arbitration provision. The Company shall pay all fees and expenses
for the arbitration itself; provided that the cost of the arbitrator will be equally divided between the parties. The Company will pay
your legal fees, provided that, if you substantially do not prevail, the Company shall be reimbursed for your reasonable legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.    <U>Indemnification</U>.
On August 5, 2015, you have entered into an Indemnification Agreement with the Company which remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.    <U>Section
280G</U>. In the event it shall be determined that any payment or distribution by the Company to or for your benefit (whether paid or
payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (the &ldquo;<U>Total Payments</U>&rdquo;),
is or will be subject to the excise tax (the &ldquo;<U>Excise Tax</U>&rdquo;) imposed by Section 4999 of the Internal Revenue Code of
1986, as amended (the &ldquo;<U>Code</U>&rdquo;), then the Total Payments shall be reduced to the maximum amount that could be paid to
you without giving rise to the Excise Tax (the &ldquo;<U>Safe Harbor Cap</U>&rdquo;), if the net after-tax benefit to you after reducing
your Total Payments to the Safe Harbor Cap is greater than the net after-tax (including the Excise Tax) benefit to you without such reduction.
The reduction of the amounts payable hereunder, if applicable, shall be made by reducing such payment that trigger the Excise Tax in the
following order: (i) reduction of cash payments, (ii) cancellation of accelerated vesting of performance-based equity awards (based on
the reverse order of the date of grant), (iii) cancellation of accelerated vesting of other equity awards (based on the reverse order
of the date of grant), and (iv) reduction of any other payments due to you (with benefits or payments in any group having different payment
terms being reduced on a pro-rata basis). All mathematical determinations, and all determinations as to whether any of the Total Payments
are &ldquo;parachute payments&rdquo; (within the meaning of Section 280G of the Code), that are required to be made under this paragraph,
including determinations as to whether the Total Payments to you shall be reduced to the Safe Harbor Cap and the assumptions to be utilized
in arriving at such determinations, shall be made at the Company&rsquo;s expense by the Company&rsquo;s then current independent auditors,
or such other nationally recognized accounting firm selected by the Committee prior to the relevant change in control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.   <U>Section
409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(a)    <U>In
General</U>. It is the Company&rsquo;s intent that this Agreement be exempt from the application of, or otherwise comply with, the requirements
of Section 409A of the Code (&ldquo;<U>Section 409A</U>&rdquo;). Specifically, any taxable benefits or payments provided under this Agreement
are intended to be separate payments that qualify for the &ldquo;short-term deferral&rdquo; exception to Section 409A to the maximum extent
possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay exceptions to Section 409A,
to the maximum extent possible. If neither of these exceptions applies, and if you are a &ldquo;specified employee&rdquo; within the meaning
of Section 409A, then notwithstanding any provision in this Agreement to the contrary and to the extent required to comply with Section
409A, all amounts that would otherwise be paid or provided to you during the first six (6) months following your date of termination shall
instead be accumulated through and paid or provided (without interest) on the first business day following the six-month anniversary of
the date of termination. If the period during which the Release must become effective and irrevocable in accordance with its terms spans
two calendar years, then, to the extent required to comply with Section 409A, any payment to be made under this Agreement will commence
on the first payroll date that occurs in the second calendar year and after the Release has become effective and irrevocable in accordance
with its terms. Further, to the extent required to comply with Section 409A: (i) the amount of any expense reimbursement to which you
may be entitled hereunder during a calendar year will not affect the amount of reimbursements to be provided in any other calendar year;
(ii) your right to receive reimbursement of an eligible expense hereunder is not subject to liquidation or exchange for another benefit;
and (iii) provided that the requisite documentation is submitted, the Company will reimburse your eligible expenses on or before the last
day of the calendar year following the calendar year in which the expense was incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">(b)    <U>Separation
from Service</U>. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination
is also a &ldquo;separation from service&rdquo; within the meaning of Section 409A and the Participant is no longer providing services
(at a level that would preclude the occurrence of a &ldquo;separation from service&rdquo; within the meaning of Section 409A) to the Company
or its Affiliates as an employee or consultant, and for purposes of any such provision of this Plan, references to a &ldquo;termination,&rdquo;
&ldquo;termination of employment&rdquo; or like terms shall mean &ldquo;separation from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.    <U>Attorneys&rsquo;
Fees.</U> Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to legal
proceedings in connection with this Agreement or Employee&rsquo;s employment with the Company, the party or parties prevailing in such
legal proceedings shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable attorneys&rsquo;
fees and costs in such legal proceedings from the non prevailing party or parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.    <U>Assistance
in Litigation</U>. Employee shall, during and after termination of employment, upon reasonable notice, furnish such information and proper
assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it or any of its subsidiaries
or affiliates is, or may become a party; provided, however, that such assistance following termination shall be furnished at mutually
agreeable times and for mutually agreeable compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.    <U>Miscellaneous</U>.
This Agreement, together with the Confidentiality Agreement, and Indemnification Agreement sets forth the terms of your employment with
the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended
except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will be lessened or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will
be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained
herein. This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i)&nbsp;on the date of delivery if delivered
personally, (ii)&nbsp;one (1)&nbsp;day after being sent by a well established commercial overnight service, (iii)&nbsp;three (3)&nbsp;days
after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors
at the following addresses, or at such other addresses as the parties may later designate in writing, (iv)&nbsp;upon confirmation of facsimile
transfer, if sent by facsimile or (v)&nbsp;upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2222 Ponce de Leon Blvd, Floor 3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coral Gables, FL 33134</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to you:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5861 S Albion Ct</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Greenwood Village, CO 80121</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.    <U>Withholding
of Taxes</U>. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company
is required to withhold pursuant to any law or government regulation or ruling.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To indicate your acceptance
of this Agreement, please sign and date this letter in the space provided below and return it to me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED AND AGREED:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELMADA THERAPEUTICS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHARLES ENCE</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">  /s/ Sergio Traversa </FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid">/s/ Charles Ence</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sergio Traversa<BR>
Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 1, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 1, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RELEASE OF CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>FOR AND IN CONSIDERATION
OF </B>the payments and benefits (the &ldquo;<B>Separation Benefits</B>&rdquo;) to be provided to me in connection with the separation
of my relationship with the Company, in accordance with the Agreement between Relmada Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;)
and me dated as August 5, 2015 (the &ldquo;<B>Agreement</B>&rdquo;), which Separation Benefits are conditioned on my signing this Release
of Claims (&ldquo;<B>Release</B>&rdquo;) and which I will forfeit unless I execute and do not revoke this Release of Claims, I, on my
own behalf and on behalf of my heirs and estate, voluntarily, knowingly and willingly release and forever discharge the Company, its subsidiaries,
affiliates, parents, and stockholders, together with each of those entities&rsquo; respective officers, directors, stockholders, employees,
agents, fiduciaries and administrators (collectively, the &ldquo;<B>Releasees</B>&rdquo;) from any and all claims and rights of any nature
whatsoever which I now have against them up to the date I execute this Release, whether known or unknown, suspected or unsuspected. This
Release includes, but is not limited to, any rights or claims relating in any way to my employment or consulting relationship with the
Company or any of the other Releasees or the termination thereof, any contract claims (express or implied, written or oral), including,
but not limited to, the Agreement, or any rights or claims under any statute, including, without limitation, the Americans with Disabilities
Act, the Age Discrimination in Employment Act, the Older Workers&rsquo; Benefit Protection Act, the Rehabilitation Act of 1973 (including
Section 504 thereof), Title VII of the 1964 Civil Rights Act, the Civil Rights Act of 1866 (42 U.S.C. &sect; 1981), the Civil Rights Act
of 1991, the Equal Pay Act, the National Labor Relations Act, the Worker Adjustment and Retraining Notification Act, the Family Medical
Leave Act, the Lilly Ledbetter Fair Pay Act, the Genetic Information Non-Discrimination Act, the New York State Human Rights Law, the
New York City Human Rights Law, and the Employee Retirement Income Security Act of 1974, all as amended, and any other federal, state
or local law. This Release specifically includes, but is not limited to, any claims based upon the right to the payment of wages, incentive
and performance compensation, bonuses, equity grants, vacation, pension benefits, 401(k) Plan benefits, stock benefits or any other employee
benefits, or any other rights arising under federal, state or local laws prohibiting discrimination and/or harassment on the basis of
race, color, age, religion, sexual orientation, religious creed, sex, national origin, ancestry, alienage, citizenship, nationality, mental
or physical disability, denial of family and medical care leave, medical condition (including cancer and genetic characteristics), marital
status, military status, gender identity, harassment or any other basis prohibited by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of the Company
entering into this Release, I further represent that I have not filed against the Company or any of the other Releasees, any complaints,
claims or lawsuits with any arbitral tribunal, administrative agency, or court prior to the date hereof, and that I have not transferred
to any other person any such complaints, claims or lawsuits. I understand that by signing this Release, I waive my right to any monetary
recovery in connection with a local, state or federal governmental agency proceeding and I waive my right to file a claim seeking monetary
damages in any arbitral tribunal, administrative agency, or court. This Release does not: (i) prohibit or restrict me from communicating,
providing relevant information to or otherwise cooperating with the U.S. Equal Employment Opportunity Commission or any other governmental
authority with responsibility for the administration of fair employment practices laws regarding a possible violation of such laws or
responding to any inquiry from such authority, including an inquiry about the existence of this Release or its underlying facts, or (ii)
require me to notify the Company of such communications or inquiry. Furthermore, notwithstanding the foregoing, this Release does not
include and will not preclude: (a) rights or claims to vested benefits under any applicable retirement and/or pension plans; (b) rights
under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&ldquo;<B>COBRA</B>&rdquo;); (c) claims for unemployment compensation;
(d) rights to defense and indemnification, if any, from the Company for actions or inactions taken by me in the course and scope of my
employment with the Company and its parents, subsidiaries and/or affiliates; (e) any rights I may have to obtain contribution as permitted
by law in the event of entry of judgment against the Company as a result of any act or failure to act for which I and the Company are
held jointly liable; (f) the right to any equity awards that vested prior to or because of the termination of my employment, and/or (g)
any actions to enforce the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing herein shall be construed
to limit my right to (1) respond accurately and fully to any question, inquiry or request for information when required by legal process;
or (2) disclose information to regulatory bodies. I understand that I am not required to contact the Company before engaging in such communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I acknowledge that, in signing
this Release, I have not relied on any promises or representations, express or implied, other than those that are set forth expressly
herein or in the Agreement and that are intended to survive separation from employment, in accordance with the terms of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I further acknowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
first received this Release on the date of the Agreement to which it is attached as Exhibit A;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand that, in order for this Release to be effective, I may not sign it prior to the date of my separation of employment with the
Company but that if I wish to receive the Separation Benefits, I must sign and return this Release within 45 days of its presentation
to me after my Termination of Employment;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have carefully read and understand this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company advised me to consult with an attorney and/or any other advisors of my choice before signing this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand that this Release is <B>LEGALLY BINDING </B>and by signing it I give up certain rights;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have voluntarily chosen to enter into this Release and have not been forced or pressured in any way to sign it;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
acknowledge and agree that the Separation Benefits are contingent on execution of this Release, which releases all of my claims against
the Company and the Releasees, and I <B>KNOWINGLY AND VOLUNTARILY AGREE TO RELEASE </B>the Company and the Releasees from any and all
claims I may have, known or unknown, in exchange for the benefits I have obtained by signing, and that these benefits are in addition
to any benefit I would have otherwise received if I did not sign this Release;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have seven (7) days after I sign this Release to revoke it by notifying the Company in writing. The Release will not become effective
or enforceable until the seven (7) day revocation period has expired;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Release includes a <B>WAIVER OF ALL RIGHTS AND CLAIMS </B>I may have under the Age Discrimination in Employment Act of 1967 (29 U.S.C.
&sect;621 <I>et seq.</I>); and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Release does not waive any rights or claims that may arise after this Release becomes effective, which is seven (7) days after I sign
it, provided that I do not exercise my right to revoke this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intending to be legally bound, I have signed this Release as of the
date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 59%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: __________________________</FONT></TD>
    <TD STYLE="width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Signed: _____________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex10-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W -@# 2(  A$! Q$!_\0
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MA*HHOG<8N%VG&-;FY9O\V>655'VD<;B'B4K\[F_9REORVYFU%O2[OT;C:Z/
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M2V2\TR^L]1LY"1'=6%U!>6SD8R$GMWDB8C(R%8XR,U<K_/J_;/\ V%OVV_\
M@WDU7X6_M;?LK_M>>*?B+\%M6\?:9X(\3>'=8L]1\/6']KSV=YKUAX6^(O@
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M"\/:U_:;SZ?\-/Z8,^V3\8<#/OQ7YM?M5_LY?MB_!'Q%;WO[6'@7XI:!K^N
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MVGO^W'\&/@K9VO[3_P"T/*_PQ\9^$_ 6H>(;*"3XM>(YY9)]4U[Q[H6J^5K
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9FIU)N\ZDU3A!2J3:3G4DI3FTG*<FDU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex10-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W -@# 2(  A$! Q$!_\0
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MA*HHOG<8N%VG&-;FY9O\V>655'VD<;B'B4K\[F_9REORVYFU%O2[OT;C:Z/
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M2V2\TR^L]1LY"1'=6%U!>6SD8R$GMWDB8C(R%8XR,U<K_/J_;/\ V%OVV_\
M@WDU7X6_M;?LK_M>>*?B+\%M6\?:9X(\3>'=8L]1\/6']KSV=YKUAX6^(O@
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M"\/:U_:;SZ?\-/Z8,^V3\8<#/OQ7YM?M5_LY?MB_!'Q%;WO[6'@7XI:!K^N
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MVGO^W'\&/@K9VO[3_P"T/*_PQ\9^$_ 6H>(;*"3XM>(YY9)]4U[Q[H6J^5K
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9FIU)N\ZDU3A!2J3:3G4DI3FTG*<FDU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W -@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^X+XW_'#1
M_A%I,:^7'J'B34(RVG::6S'#$3(HO;T*Z/Y3/'(EO"KQM<O'*3)%#!-*GQ);
MZW^TU\8C/JFC2^)(M,>8^4-.NKG2+*-2TF(HI()=-L&:(AHW&5O #&)@Z%'+
M=<MF^,'[3,VCZI<2OIR>);K3O+RSK%8Z1=2VS1Q*740L=.TW(*Y07RB4QN))
M5;]1]/T^QTFQM=-TVU@LK"R@2WM+2WC$<,$,8VI'&B\  <DG+,Q+,2Q)/\D8
M' <2^/O$W%F*Q7%F=<+^'G"V=XGAW*\KX=Q,L'C,VQF#E6A7Q>+KPK4(R<E0
M>(JU<0\2J:Q&$P6"PE*-+%XNK^T8C$95X;Y5DU&CDV S?B;-\!2S/%XS,Z2K
MT,%0KJG*G0HTY0J-6=14H0I*DY.E6Q%>M-SHT8?D5XCUC]H7X8S0OXEU/Q=:
MV\A 4:EJ.J7-E. 6#(EPUR\3/M1B[V=Q)Y*E6D90ZAOAW]N'_@JF?V2_!&D6
MVB7E_P",OC?XVL[J;PGX$OM=U:'1] TZW<VT_C3QI<VEXEW_ & EWNMM&TNT
M:#4/$=[#<6Z3V5I9WEVG](/BOPMH_C/0-1\.ZY:QW5AJ,#Q-N16DMIMK""\M
MF8'RKJUD(EAD'1EVL&C9T;_/LL_A6/VV?^"P=U\&_&5_=GPSX@^/^M> [];>
M62*6Q^&WPE&J_P!H:)IDH9FLWET#PGK$5I.I)34M0:[<,[N6_:/![PQXLX1X
MYQV$Q?&&9\3>%E#AK&YM4PN?SJ8S-,%G-#&8;#X/+L/B7B:LZ%*I2EBL;6J8
M>M'#8S"4?JM3!83&J.+G\1QGQ5DN>9!0KT\DPF5<72S.AA%5RV,:&#Q&!J4:
MM2MB:M%4H*I.$XTJ$(U(.K0K3]K'$5J#=&/7^"?%_P#P6R_;_DO?''PY\7_M
M+>*?#(O9XH[[P)XGO_A)\,-/G1F$NG:'<6NM>%M!N7LSB*6V34]5U2(E7O79
MF,E=7:?MC_\ !8?_ ()H>,_#I^.>H?%^;PU>7"JGA7X]2ZA\0_ OBRVAD\VZ
ML-(\77E_JI@O!#'(TDGA/Q5:7]L'26[#)B-O[N/"'A#POX \+Z!X)\$Z!I7A
M;PEX6TNST3P]X=T2SAL-*T?2K"%8+2QL;2!4BAAAC4   L[%I)&>1W=O.?VA
M?@'\-OVG/A!XV^"GQ7T&TU[PAXUTBYL)A<6\4UYHFIF&0:3XFT.:12UAX@\/
MWK1:EI-]"R/#<PA'+V\L\,G]"QXKP<ZJP]7(<M65.7LW2A0A]8A1;Y?:*:IQ
MA*HHOG<8N%VG&-;FY9O\V>655'VD<;B'B4K\[F_9REORVYFU%O2[OT;C:Z/
M/V /V\OAA^W[\%8OB;X&AD\.^*=!N;?0_B7\/+ZZCNM3\&>(Y(#/$([A$A_M
M/P[K,4<UWX>UM8(%O8H;NSN8+75=,U.RM?NBOX6/^"'_ (R\4_LX?\%0];_9
M\GU.6?2/&7_"UO@]XOM;?(T^\UGX>)KFMZ/JXMV+-Y]EK'A*YLK.8L7M[+6M
M27++.X;^Z>O'XCRNEE692HX>3EA:]&GB\-=N3C2K7_=N3UDH2349/WG3E#FO
M)2;Z\!B98G#J516JPG*E4MHG*%O>LM%=:M+1-.VC5JE]?V.EVDU_J=[::=8V
MRA[B]OKF&TM($+! \UQ</'#$I=E4,[J"S!<Y(%<U_P +#\ ?]#SX/_\ "FT7
M_P"3:_(?_@X9=X_^"1'[631N\;"S^%PW1NT;8/QC\ !E)0@E6&5=2=KJ2K J
M2#_,3_P2T_X-W_AO_P %"?V,/AU^U)XF_:C^)'PXUKQKKOC_ $B[\):'X(T+
M7-,L$\'>,]8\+V\MOJ5_X@LKJ=KV#3$O)A);H(I9VA0,L8=_!.T_T$K#4=/U
M2V2\TR^L]1LY"1'=6%U!>6SD8R$GMWDB8C(R%8XR,U<K_/J_;/\ V%OVV_\
M@WDU7X6_M;?LK_M>>*?B+\%M6\?:9X(\3>'=8L]1\/6']KSV=YKUAX6^(O@
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M"\/:U_:;SZ?\-/Z8,^V3\8<#/OQ7YM?M5_LY?MB_!'Q%;WO[6'@7XI:!K^N
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MVGO^W'\&/@K9VO[3_P"T/*_PQ\9^$_ 6H>(;*"3XM>(YY9)]4U[Q[H6J^5K
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9FIU)N\ZDU3A!2J3:3G4DI3FTG*<FDU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex10-4_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-4_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W -@# 2(  A$! Q$!_\0
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M<_X-)/\ DP+XV?\ 9T_B7_U6?PRK]!OVG_\ @OQ_P3(_94\:ZK\./%OQLO\
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MP6Y\+:G< R7-[\>OVBKJ<JA!9F\+?%:265D!?:6PTLOS%5)<YVC-?TV_!_\
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MMAZE.-2G*FXRYU."48KG<G!QJ2_CT_X(HZIXB_9W_P""J]U\$YK]IM-\2?\
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MXK2&PBL-0UG0XK!X)]T[W4=S,\@=8FA"@/78?LE:1XQT+X^_MKZ7X]\9VWQ
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MG'X[%4:>)Q?%&69I-4\5A5A\-4RSA?-:<Z=*4ZTZ<ZM2.$][\*?$'PAXWO\
MQKI?A?68M5OOAYXKF\$>,8(X+N%M&\40:3I.NRZ5*US!"D\B:5KFEW9FM&GM
MBEVB+,9$D1,;2OB_\/\ 7?!GBOQ_HFM3ZSX7\%:EXRT?Q#=Z5H^M:A>6VJ^
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M-+':VL,UQ<0VT$5Q>-&UW/'#''-=-#&(86N)54/.T42B*,RLQCC 12% %%%
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@FISE4FJ=.G34ZDW>=2:IP@I5)M)SJ24IS:3E.32:_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>rlmd-20251212.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSa6PSaPtypR1aYkxs2tyHUkanyEtAj2PTyOE8jO24SQL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:RLMD="http://relmada.com/20251212" elementFormDefault="qualified" targetNamespace="http://relmada.com/20251212">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://relmada.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rlmd-20251212_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rlmd-20251212_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>rlmd-20251212_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>rlmd-20251212_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="rlmd-20251212.xsd#Cover" roleURI="http://relmada.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://relmada.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 12,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RELMADA THERAPEUTICS,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001553643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-5401931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2222 Ponce de Leon Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">&#160;Floor 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Coral Gables<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">629-1376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RLMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0269660-8k_relmada.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relmada.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0269660-8k_relmada.htm">ea0269660-8k_relmada.htm</File>
    <File>rlmd-20251212.xsd</File>
    <File>rlmd-20251212_lab.xml</File>
    <File>rlmd-20251212_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0269660-8k_relmada.htm": {
   "nsprefix": "RLMD",
   "nsuri": "http://relmada.com/20251212",
   "dts": {
    "inline": {
     "local": [
      "ea0269660-8k_relmada.htm"
     ]
    },
    "schema": {
     "local": [
      "rlmd-20251212.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rlmd-20251212_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rlmd-20251212_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://relmada.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0269660-8k_relmada.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0269660-8k_relmada.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://relmada.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001213900-25-121461-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-121461-xbrl.zip
M4$L#!!0    ( $@^CUO?A*P7,Q<   R?   8    96$P,C8Y-C8P+3AK7W)E
M;&UA9&$N:'1M[3UK=]JZLM_Y%;J<?<Y.[N9E\PB0A+,(D(;F#:3-[I<L@04X
M,3:5[03ZZ\^,;(,-)@'2!+J;KK8)6-*,YJ69T4@^^.]HH)%'QDW5T __E!*I
M/PG3.X:BZKW#/\O-2KW^YW]+D8.^!<V@J6X>1ON6-2PFDT]/3XFG=,+@O:14
M*!22(VP3=1H51Z'MY%1*2MZ>GS4[?3:@<54W+:IWV*23INH/B\?'IY.F;:ZI
M@:;XC0<DG9P;&IXJTP[^QKFD\S#0U IMFG6:6EY3U30RLK3W'!Y.BTF'T:*V
M$N(,,V2W1XVS:7,KO/VT:=+B5#>[!A]0"UB((V7C*3DNYWR#Q$W6"0P$GQ,]
MX_'%<?+QM.2-,\><X$SQ<9N:$XHK;(;<'DQX #WDK-?0-N,]2H>3QEUJML6P
M[H/9QMS0F!G:6CP)-.\8MF[Q<3@B[L- !Y-;\T/#EX%&C;/SZJ059]J *C31
M,0:BD21+<A0UAE&E%"'XY\!2+8V5#I+.S\C!@%F48/\X^VZKCX?1BJ%;3+?B
MK?$0"-AQ/AU&+3:RDD*MDM KZ0QY\'_Q.#E6F:8429-9^^2"#EB1C)31/JE7
MQ2]W*;EV=]/\MUS]5"Y?P0]$C,3C2W9.I^]PBG>^J=UY4UM^E$QJTFF-WMG"
M'0-) =SA;WG = 7^6<<:[=UUJ6:R%4:2?2/5=.#!N )#<:K5=86-3MGX+@5V
M*9M-YS+IY8?-'0&%JW?2G:OBSOCPU0I#R'?-/N7,O)/OA$%SQC#%=RL,4T5,
MKMRATG,(+1J[;2AC8EICC1U&NR!R12*EAA9IJ0-H<<&>2,,84#WF?!$#^%SM
MHF0KZJ/735'-H4;'1:(;.L-GZJB(4LHXB+[XH"H*TU$/\!.TNK ',$['D?&1
MU6#=PVC9O.RBA,0E&?Y&B:H<1H]IQTKAGW24Z#!I@,748D 0HB4A"0?)P,BO
M@97QPPH5E6AI*BMA@)/^.2,:G'49AQ65F>(Y6LFB*98_0(>(-:W8YX@9UP9*
MW%.4Q,A4HNYC"XS"8=14!T.-H2%PP01&=D"9ALU=2-!(L+WH3EY,=&;RKGGR
M6C(Q8>_+R=>J@@^Z*N-$(,Y"5Y)*_31(F]G.$V#),&@NK"$0TE#F4("UG%M5
M:K'2%'MOG.FSV5X@*@OZ>$]F4/)#][YSR1<@J:VK#CU!N6:).&#4M#DKN4I8
MA";>4-ZCP/@X5OC@CCXO&M^=O&BS)H"IT9@% AH.C)LC*/84PDXM@T^?KCSW
M6?1"QO1!K#+=&*CZ"S!?I,<LT)!AO<?^Z<^2T56]J:8Y*N_:O(,D]"U%(I&#
MX:J6=9\,*.^I>I%@T]0^0;&+4TWMP5<=T!;&]TF;=AYZ'/P6)=XQ-(,7R5-?
MM<#R'B2' -:_7#1LC<6O:$^LE'Z;_:0J5A\Q2OT[&GC0-CA,(FX9PR(YT@ 2
MD0$3T]!4!2 [#]N&91D#[[DT?8[3C)OJ#UB=X-MHZ3__DG*I?8<>[O\^Y)(!
M[#9 KO8$P;9'N_='X>:BWJI52;-5;M6:&\6D6:O<-.JM>JU)RA=54KNMG)0O
M/M4BE<OS\WJS6;^\V"AZ7ZG9AX#4,F#@:J*2('(JFREL#B5/=C9$CN/+QKF+
M@CFDNC#FZ D64FGAZL;C5:-CHYN$\<1=9^*&3QWR'WO]%&_S[OEIK@-CKNDO
M%?S^DA]FM)2/G\[Z1P=)Q+;TV[(-5*Q1NVB11NWJLM':J$)=V=RTJ6X1RX 1
M.QCQ1Z0T,3B1LCO*+C&ZQ.JSS9HDUK&Y:JD HC;J]*G>8Y%RQT+4I$(Z\WM*
M$7JM2($&&QK<(CONYPBCX*,PTR+L$88@7#QFRF[1119H-6,II!E+<25\WYKC
M&(>;C$^92W64[E?Z5^I*)L-)*AU&U9%55&#T ;3M*W0\!JR9'C0I4BK,I 20
M RJP#ANT(1Z1Y!A!2!^6)J@[L\R6768[(6V#]503TWT69A/">=U(??MZ9E$V
MOI+77AXD:3Z<#L*.EAJUL_-RM4Q:)[5&^:IVTZI7FK%(_:*2V#J>[M1&,#$Q
M(U1!/IE)A)K$'+(.AKD*48'PEDG 8H$&\MTMD#^+MC4&?30-*-C!Q'X4M P_
M#ZFB>)]7QB\01V!D9'%OD$?&+;5#-0]?""G<$// 4F;"C9F((I&=QA0NA+3\
M[[#I1UTQ]R'N!2 IC$!"]* 0T(.ZWC$X&$J1\&Y:8%HJ3D:X8B@+U$+K-;+I
M\</#E[*RK@G$7#PF+2PVY,8C2M.<#93G]>997*.E"_9(%?JLRKB_6LH<(UPR
M(Y5=@9@P1; CG/B>B(4,N '.9@.</58U!D2 )2*<C9\?6X43O?+C_*R_OG5+
MSW-I"A=S85(\74CEY=^8*T<!KK3HJ.ZF SM"CI]CD43K6O^RW!I9KUB 0O*Y
M"Y"(EC+9>#:3 M=26I)A\!]?Q^ZM3MD=H?#HG1O@E7-R#XZQJ:C";3]H\V0I
M NN1ZK<0N\])UHIRLP:^%6,P4$W<4B:H$L2A\8:1JC>:I#88:L:8<8=J04$@
M%T9B-Y3!2;&"EGZ757P-RS$K^$[3R>B9PL^R*$%/MJPHG)FF^^-,U9D4;DU^
M7/0EV1AEF^7V^M8D.V]-0A"(EF3X0ZX,O<.(PL@9 ]$ZTAZ511YM;':.J1?F
M*(?/<= ]S9\T^!,S5@O/ G/,+3-'V1/-8\T HS2W$>8ID5"RV=E5PF97@5\O
M><MXTL/GUK9J?>7;[>53>6_]N>TMG-L4?+14 1.JD4^H;>8BCI'GW0]W5&&U
M+_D5N'E@G!=XE/WZZ77[1NGVY-SZ,\LOG-D,#M'2\=F:_DC(VC;1[_=T4M[-
MU.R%\?3* -==^Z8.%\<(%XW+FGFK'_W@KY#5PD*.!C"(EM)I"9-AV^:QN,AB
MH#SD('GJ$)2*C5C'MM1'C)]AU67FACT"(")!*F[QJO_.L*?IF?_\*R]+>_LF
M]-?8L&_H+*(++RZ&GJ9FHZX3RAD%F5;8-,^XLTB-T,:6H?UBQ3DYMJR3'G\\
MO9;65APYD#_TPXR6]O*Y!8JR&[Z;XBU59P9HR!72X+F(1<UF;QYJ7Q_&S?SZ
MZ =29K-PHZ6<7(A+Z;U%\]B2A.?F$T[.HC!OR18L4KZ17URQWM&('AL<V.MF
M'+E((L%'ZIA6T,,N<?9%  8N[D2CII?[_VU,VKUM0@@W?@9XI<_ AX# F=#A
MD!NP'(%+%&D;(])FFO&$9,2'2&R2CY^2KJJA;5--,'06TQ4@KV4 A0>V9E&=
M&;:IC8D)(:/9'8N>;@>C#1@YD:2S?>9+$1- "UFGC[UG74,#X- O@FE %6-E
MD^R8C)%/3&?H@M9UZ&N+()^4$W+"07>W^+9D%%^J.D;&T#"15?5?1^M#]<[M
MGTK(8B[^26NL:X4I89<.5&U<? FS>2=RP1[;5ZY:($F8%;%U-]M@AB\B]:]/
M0_T^D^L4M+7WV-J&H3&JB^+(F>4ED%D.10N96MC+9/87+C'+>6RN0+UDXUP<
M8&Y^),C0MS^-I4(D(V=='4+E\>T-XY;PCK1'*L<-(J=3"6CXKK;O9?OSH23/
M*HFW)].$\*X#/-5[YV"?P4AKX1IRU5?N,X9U8M8S;Z$A@:S^/$[OK!Y3!$ &
M'0SF=4/*4)BA3SV\>HF@<F12":?EAW[\2OKAQ4]7G*&EQH)O466%G@F_['87
MA2-5\_;^7+F_;ASUWD)/ ELKBW%[9WT!1.(='R8OKBM21HG+.^W=Y;3':?NA
M/[^2_J3#]:=NFC;C+VK13<K\VJVUAW9SM9S$DEJ4?4:+YC#<>EU*LWAFI[.<
M+KEMMUF7-EKSZ,2.C#,E,IPOUG3PE(3E<@-*H'#Q(__S0OYGB1H(G$\<\69X
MJNV)T^%K"R-:>.H3V<1HIT\Z&C7-GU?XX9C/#99]M#@5N>#F>- V- ^1;9K>
MS^?HA5L#R#SS9N@(!K@[5=O5-U["U(OWVCMR*A.3T_F8G,WN_HR\XC-[7:X!
M&DMR6TCMHMJ<D7)O*-^JUL/ZF>[ 3O,L7-R&'0P,G(/1>8B1/U*)5$H"@>'D
MD6HV(T,\C8B'O=;<S7SSS:40(E==(KL:XRA,.(6Y^?W;4^X38]IJSGN PH']
M[@#0: G/=V\QZ5I]%KXE<SPCJ)Z#L;B2^;)63P\EV];/NZ\JV41=#ZO6E/-A
M@NS'"^Q%N5DM7R^@MS/1"AVJ%D3WYY0_,&OASNU;>T;KIW_?VU6KZPJZHHRT
MQZ0C4OPPW$/DJ<]$C=Q,_ETU"<@1^+$(L4=@Q">KCQ[M$'/RU"0*ZZJZ4[[M
M)!Q36<^SFLDV.@=0TF0'I[^W+Y*.7F-5%'X/L? [8G#7+9;;<3EDK(!O[)YJ
MF0R*+O*TGV_8Q)N0FZN]OK493K\$NA;.,[]Y6#EL7)QE<4HM/)B?!,B* W'!
MH9ASPSXY[N9ZY3=)LX34@80BMW1L^ 8<1!]M:ZU$-T3O(ZX,82E#F!'QM@1]
M]J,/)H)I$'R!B= -$8K9)A.M !]WEQ!OT%'%?IUSDP R6<BK-D;@3RJ(+YH;
M':9J\ AGCZH)_<#P4+V#J5W:$7?28&.\ODBA7($X&_<'<?R0.!!B[ATZ"0']
M%B7Q2@69B)-OC=J$]+S]2>V7$?"!_LD'['T'Z$,#&=\!_*TZ8+\ZTP*D0[SV
M <QW&Y-+@(U 4CB.\^1Z)K1S,'0(*LD8.[K?>'URPI^<F;N.IE=;B@1A.1 _
MT%0(S)3#G;R<+@B-<>^$F)L=9_0AWF9@(X "0T$1_]"YD*%QCO[YK(W>+%Y^
MR9D(S:9EQI='\N>-9O-*K\DC+46NYY!^*0\>E@/? Z]:S+=NL8$SYVPB)3OS
M1F?_I;1MNU1E$ I;-A=9B*K*834PN(E%0A5 @X(3>RDJ++FY3VJ:NU;XF^Z3
M\G!HJ+HE,KOP9+X?>A9,-_&"E'&DS#FN+-C:#&N>\//."U@FT<K&1>G]'8]+
MG<P=4XY%<)4^,F!9#_)MP=?BH+>X@HU 0,SID-D@8H!@7>\DR [V0CLC0_3H
M.<7P2=K?=2J='L%G@,6?#ASW!/P)\&C$R4,EPL1!&,%\VN/,2? +!T4D*?$\
M$3!ZMF"7 VSQ'#R0-@//!KR?;A?%"YI0@?!GJMN4CXDDIIQ+H%/"@( BQ#([
M7&T#*J*2*8;3CDRVM>''P)QD2><@3^I1PS"/X?#N/&-8E4ILW2N-ZW)C ) ,
MD_D0 ,E%ZOG(AF-'1!"H"K! OQ'>CH;GU1%65]6@GZ#03!R'=)UX7KZ33UBV
M->0J+#22RW[?QD@'HCELY/+O0"W5O!E')HHG$OV FKQ?FTZZ[$T:3R>47(Z3
M'7=&'6H*F]!$A]<@+4[Q;D\:(^<4B='L,]VP09X0Z4J?<@T#45B#=]%V+*!*
MQ>8<(;N7#N"A+E^MW.I4\40DYY!E#O<K:FOD%*S\>#?FIE4=S@F2F1'D[_2T
M&\ 'W6 P!OCPDSO18F\3)V]T!^EEX"!&<XRO]%76C4RDR[/8CO!L$-<%.T;_
MJ)4>%_ID:=$^N BR<GN%_:56_7.>F'!U8@Q-JJ$F/:F:ABH!+B6HD+!X?^SE
M]V+P#TWU'WEY+R;MY436'&_=2+S#&KV4M'I"H&YJF08<IN;&4Y;+(5Y'AU&X
M3UD^U.2741/!S&5T)%,HQ/*IE-"1K)R)[152;ZPCSO\A93 ?DO"S):'N>!7.
MC4B8(0,'$^][%%Z(NT< [K'(T5%,YL$OX!_#($X;?- S#'2:J0F?=WR=_-YL
MQ'5?=+QEM6UK&K/ ;YG(H2-X;4!$%]<_.Z<) "N.]Y,3]MU&Y]<@UA/38'D6
MER,)/[CC<P/)#K4$$%>8AYH-40.P@P%(0X</Z DA)HX_[CKCV$-QKXSR37^7
M#.E8"!!TH$2S!R#6]N -)5[*S6_M3QCU(=CO+]B?4+ ;0K Q"^Z6IJ!E5,"#
MAY4/8S-)C@MQ]-+9;094TL59%ST@6Q1C"73T822\RIP;&DAL8%,M)+! [U\B
M3=SA)Y=.."2BAN^V:HTQQD6-@7CH2D-^3B.\=;1+RK]*LV &D0_-^ATTBZE"
M@R:GM#CK&2CQ0MO,ER0/=_Q4B&Z]?%N?40WTI\UTT 3+%*KG&/J((XYO*!GI
M]')RL0&7>R89L>.XW<>3?3#7[=[]\+M_&=5!O? 8NHSKG<WF8X6"<+VS^5RL
MD'D7SSN37Z 3,Y4O<3GS++D_I&.;?''?K?#K_YE+#L_[\Q.#]58N_4^92)CS
MLJ5AP4<@_*LHWYO'"^MIV$*W/K*L6[]]FO&A#EOAY#\KBDOX^6*O5S- RAU
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M?D</+0PLE*M)FK8IJYFG--8*3BAZ#TE&1GAQ'!XG6?CW/Z-Q4"^R;+FS9VJ
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MT>&>Q.<E   D<="SCFJ*<Y'[Z^LD?#-POH(BT-T)20(O_1LI F+0TCD@L@"
MDBGA0 PJD$"N9JL!%YS;QSQ'9/W3/2<E!QBA^&X!7CH3!,QF31 $*$!?\?MC
MYJ')C*2.TXJ[H]Z?<+YK9ZEM_L,=9)OWTT%V!_CYX"F[D6!M3SO1B-OOL14W
M()M*] B48Q<I@ET&Y3D3:N;S?"E.IR,I99DT"AFFTLAM*7PFKCFWL*P%FG-"
M^V$@^UL!*!C;I@:54GNI038$PN'4QSYB!HDJX_@\%HI%/ B&2S*LUZGML,#+
MN%0:LI%0)&%.CK4#SH!1EC;CF^K@#0$J"=7$R?TX;.\ SCO!/=HD"1(%[9?
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MB%Q8\95C(#L0<*%N"1>EB*?M5,OO!"*)0,^25S2L3:_T$<MA =EX [0[7ZG
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M<7F!EG8Q^4K?:;>M0.CK*IX4X,=0TE0J9M(V%'D#<,&+SO6,""\L7[)/*/]
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M0M2%A<1*;M;!!3A<TLZY*7TI3DX]QV>Q."_/FTG?3DY#QMC#F51DH$1@N]1
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M\L-1/#4PD<^U3<]:\Z?FH3QX=9CW>V=Z$F<C58S4L<ZF<1JKTXDNXYFN*Y/
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M5DJ/4(!:_-QML^4R(2  M-/O:=S?!F:8S=?4;_!=45<J,U-#,@>['..<8=%
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MM5/Z+L#F!0T1AI:"7I,B+R)[ 7. Q4HGW-D'/JJL*$#6Z]D@#(/N0;?2Z-<
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M&_-0/)PFK+3HGC <&(WG/G0GPCYIKY<0 )C$4\^%K@G)(_NWR>O^R\3Y HE
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MLJ\.WZB]@YWA+R?_H)DNMR\?DTRC$;PY/"8S9O@.3K=W)\/7H+*?#@_?]7M
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M@MMY^%>"<(.[%G^[3^N]=7I\><_O"KYF4BZ7],ES/B&1; 3RD[0TZ)7!JBB
M5.>U+ODB<_+8UUES*PSEG?$Y*ZI74;IT-#HK0FV6$K'"DA)!51%KM\EZ7]E8
M)1]$5I#_N*4*"^"[@%[.BI2N3UFT4>!8FDJ0(ZP*!RINTC[RI(Z8SL?Q."C(
MTE'F[M@) =1+T,D/IO"8*_Y1^$VL/DS!;IM]WNRD,C1<4IK3B,'@8-]Z)R$[
M4LO<YY(AP$72<>E]-><F(4_>PW(=PLZ%A_H&>0B.$;KU16U=GJ,QUZWD%.H/
MET0:@^K^_TSE88$+G+NDRPTWE_)X"PCHOY>7M;[VK+4"5R /U]<V6-^Z,<36
M8&TY4.P&\[^DY*?4DTP[QG([K;J]Y7RU3$.>=W\?+A@5_A;<[:^-*>-_D7\[
M//W0K<8]OWU!?NIR?G-M+Q%7-YJ+V#W523+S50[LAPI8LU/M(A+#F:J;8H:(
M6>9!9=,Q. H^<W?K62T.8S,BH(6=A+57\<DEB \:2FVK)E-%$D]:XV^NQ7:W
M*Y/7(#@S!4[#A0)@V*=M&[AQ^GW[37;ED76_\_X"[S^^Y9U'&AU&Q%C/+[%.
M-[)N:T<V['O/<C\^RVW>*LN%^<=Q>FXP-L\>=P'XN."9KU;IG:<^D$'O(="*
MY7HR*4RBG86W+&1US[8_/ML^^;YTE/:I#K^^W'UUL/_SSL'![VIW^ Y7BS"W
M4@3,<:5!EP46,4)8'M;Y03<_AP#NF?3'9]*GW\-Q'J!R439:G7-$A'.E.V@)
M.NV]7X>*B4FY,K[AV=HZN$1<P)FB:=]S[(_/L<]NF6-#EQ-A \-[YY?:60Y9
MC[ (@:@QHCFL8QC FOG69?K3$AQ1M 8!6"\+CTJDLX7Z0>P)R/C_OCO\#5@&
MI#RF6OQZ>/#^W>G.\1#_QNQQ=7JH7!**2[FXM-E+4=]-,#A:@L<V>?NZ#@+H
M.>*(#.  L@[/G@! 5-$U2&<A03LEQ]EESH#?H5PRP U[=(IW'9&1G)JT,<+O
M=:]_EI!X_CT<:UBK,U<KSU;9<\+^D>$BP[&KAE)>#('8&,KC$#A!47,I4\A%
MD1H'C;_2I'-]$5Z3$Q3CQ,L0,TEQ"D:F^'XCOKV,+Y3"RY#TIQF&I^YWPX^_
M&[9NV8 .[0[!P:L8SZ;?=H:_[A]C\B.8(>IX^//;TQ,ZIC@7D@ZD &?4 +RN
MDQG"L*ZGS]3*QE8[T^+IQD"]'+[26 7U#Z#-\-7J-IXU]ZS^P[/Z8/W[X74'
MD10$\-+T*=)ND,%CNB[<W4L7M,)2W881!(EFV2M/&(.5J%IWGPU=?B5HGR7=
MCAU"*L*DRS"&_'6WQ-*-<.-A9#B2*=(NH%VJOCVFO)RS H2*1PI(6?2VN>DB
MZPC,KK3/I*-R73<78_^Q*VZUM_63K1NM#W1"=9IK1*3]WZ7_7:<RS^;@1L>%
M94K4";%,9V3?:-=\2UB. [!]F^H/UP"";@5 T(,8#.)[X"<!/S>N#_S\1EC,
MA55]M'OX^G?<!X_>GOYR\.K_ U!+ P04    " !(/H];<>/TLPDS  !2!P$
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M;DAU<#&&F-50%LUTSNA$9B!3M:4"%0@%[2AN>R5H,?F*[%1-2!C+R!G=,GN
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MLCZ.XS*N*I>0@: ![!"U'.\/;,&A+/JGX7*U#]E"S4/<1FN24"IWWE<S^FJ
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M>J'#U%14'( KF]XS^6E)A]359R"V3$%LDD,2ZR\BFD<;+JLK:70@J8YG%=F
ML0"_4 M[B&$M8K(*5Y7HB4!<$J:]4@>Y7;$=QG)IFD$M7SS&R:1(/9J">J/Q
M:F^M+9,N;&N(LX1?LFTYURMC*7E(=D2JBX@>?*L*B'4C'@'Q'R%%D: .BAXA
M%R?H2,['::,[BE+*Y(FGW-[81)=!"BJP"B!.@*<Y/LK0,G%NJ6-F/N$E:KDA
MK)COX4CU0PT7<[#E\& )JW>'0W>(O4,*_GEOK#HM70 6IN02RH;A+Y5&%P 2
M@K VXJ)Z63:;$54_?&;"$[*!@<B2'RO@"XBPP/]LL027LWQ_: QEGC]?Y3H3
M%!(B)W18U'BKG7L!@(,\<$38'Y/I1-I>.-<TNMPP7W;>@2E<6,2X=M%>>LH?
MM 3Q%"[3M-]CB4\<N97Z>2E>!C$RDC_XKS/\"M_B/^%O,4(P<P?!,^8$VZ)D
M?,B >%"7 JR#!#LB2L3Q,U+XH+)L?_.IJY\#4IP7 ,)P'!F&,1+M5QQ>@]:_
M+#:3L'BT$# BM'$E,HECEUTK4F!%;Y^1-:=S"?2V:U"J0/D0,G:ZV* ?+-F9
MC.4$D3%4>/ZV)=4.CAXIC-M#@$E%=8SW^=2*'6)O-7HI@B^Q,OP7!0RI3KQ0
MJ^*-N+]M>><@;DG\5T-[G#"Z@6LA)P:4'9E 8#VZ(G3JS@LYW\7\6UPJ!(O!
MGU EE3HDS1CC0,C*=-F'3#K?W>?\2)'KM!$[]CM4&YOS44=$-[#QQKSX/E^U
M^/JZ$CZ&$K'5M1U!!T#N/E6\7335(]F/4(8O&ZZYK_,$]H7FC,#/,^?H\E7.
MR*B;HX60RC*V/&WPJOF,U9I4+&Q6,9G6;<^2-&N(;#$.B^/8+TD<'Z##L;$=
M%$>&A-@6J1[CYZ!^!<3G[<"? [@5/!'B=BL AQSE,KCX5"QHF+'MZFJ@ H4T
M5*@*(0IX"]2C%*T/V#YHLQCH&185$HVU=#HFURHI[/'RH=N) S!CI;K6@GCF
MR$T;]EX@R,H1+$:GB-M%E%1:PU1D *8">;QJX0NR7*ZHY]5B*;3 \T3(>2:1
M*\IL.'!9O$4,>HFZ8-,T>2#0X=?IG!0H^2U8W[-2.NMK)-'LE,#/RI"XH?:<
MFFK:<' C\680.PVA&+92*89\QG-=?S[K/%^2"C3T ZHFW&=,YU36*.AJ@CU"
MO!<.3],)L\M.?1\"(2%.KFN2AE$S\;O!!2+0?B_*3Y'[ZYIHXPE&8V!%J  D
MZKC)M&..._ (J$&Y"I_8\1U@< 7D!)>?N4]28?(KJG956*BDQ!E6U2^NK4LN
M7GJJ8UYB 'SI99Y@:.FM0[9-&9^\ETU96P/#'\"8JM3P$8G+B:4'\N/I*N1B
M;9T!R+BT@\ BM#!E7L6)P-6Z8*E[#->:21A^6J+S)-P"K1KNIL*S( $R'Y7*
M:IUCQR U#]G GF&M=*Z>'@N$Y+[VCD86P5LX,*<3M7[TP]N80O+]AOY>\K?3
M29B*6M%0S'S@Q3WSI%^TW&"*",UV[+;$(J.720:TAXB^'.<;:>/10J@$ZP)O
M,67XN'JRNK>J?JK@GHDXM+&N=,U_5OK/5=750CH<L@Y.FTHF3Z?<:LQC"_G?
M.30"SKV%-$,RA.J,O*NE$'<TRDXX^HF$5?Q=LY$5;50X5-:]BHLL5F&O)3&/
MA-[*JP]LH01,Y: S-=021>**Z=E0[]:*:FZMZ.,1^/@K3X'\55M5^VAOYP/W
MLY'5_2(7-<G-BX-4]CKR;X2Y&J>YR[8H=S'S35R;FP^NS;9K<_/!M?F=$/K!
MM?GWY4AN83J ;R>Y,Q.++'D$[*P9P>OJ*7;_6G\:F"*]X$+,2'5&"$JFS5=N
M_-%K8]ZU^6)]@P[%517;>+[V5G))0ZNR"=JT!?%>)+^1YN4MC5C^N#1GC95S
M6PFIA75-L->8C9)JR;;WHX)\J/G9E+]P/(Y =!_I][;8UNI>$,JHK5IZRUT[
MX&F!OIL/O(4J- =&E ]!/AF7960+L'-"18+]4>OXLCOF/O]R&E^&XV%<7%&Q
MD&YS:3:WMK:LWC! 3,=ND<<(]@8!EW+=P?6MY\^N;#-!I6K3EB&3Q#D^P?;V
MPNK&;*V7O4SB2S-I)JX3$!XM2'U9Z@HH8B2NS9U#"4R\GJ6IG/_>;[N[P)-X
MJ-4[$)4HVWC:7JOA[>>Z9FOP"D+48H?M<2%^8@Q,PS84A$&=O<DJ.G.1; T\
MK_9E];IS+;7%.[^-Y>XR[.:EPZ@$1D@O9O?9'B@#LW(IK*X:IPW_DP2FR!_+
M)$XU*PN\4^D")1>,-:;2C$9B,P\@;D0A],8I$G0X3J2U-.K_)$,"#>$H8FI6
MD#E;%LCA.M-<"Y]".#FJ.PB$7F$GH,V5X)R()>L9Y!" 4G,\!JVD:SNF_(GE
M2()";K@ ,=TLGE3-S>F,-]U)R=Z.T2,MR(2QMX)4XO#%PU\B!N.J=A;!4R+&
M2\X1:]6IP:8.>&SR&-</Q40HCD?A"XA:KFTA$',AX>55S$G!L):Q1B43W<R6
M[K(9E#> .-/^7KP@EJ(&EL+V74&UQ=U/5*^2,=IQ['YLI-&2=0)0W@(7-X;Q
M+/%"=N$MD:DFNA-3-_=64TF+UT&\D5?IL(Z!O7W7;F8!->L6!>X0M2XEL.I[
M##KZ1'KIB(F@-AE&?7-#M+)DVA;+1>_"OGU;KVBJ+7IEAPFZGXE VWPR9,M3
M3;Q9Q0 *S/J(R!0;=.SEZ<F45>JD&.44IHX*<Y-S:*VA8"')5_'S4CUXBEXJ
MG!\+O6K8"#<(E4HD$#<PXMPS+73]25L<VES;VKF_O7P& (&WW %;9$*N[KT
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M905CV"J.X7UE,EB#L7YWJP@V@'$QL=T.S$[O:-A8/IO V#2_U:6")6MX=TF
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M>&@Z+?)I8:)2(S6)\PR^;V*V;(D.R.&_[ SI2 5'7S#A&>L(Z$94E$P*&WL
M*D4[ADW / =Y$:7J+:[5 NU^D\*Y)=%=DYL7]WQ+!LM(;X*+,HP Z,,J!?1*
M]$4.9X+4'3]0@\J:# [NZ65>$$\J80W C8!<9W1>B TZT\7(HZ9[A2_'$ :?
M/Q;\JG7(Q#EP7CYD8%QC U=/T&>2)V9HX!3A#0,_QQ&NUETLP4I80&5Y\0-M
M2Z6'2 LM?NXNR,+K' ( QNEV--Y, SM,9ZOJ=_@NKTJ5FHDAZH%3CG#/ &VX
M];(U&%Z/<OQ^&A5P;Z+IN$=?,"/4FK;R$9Y0@/M# !" +T*&;O/8T)UDD!%K
MOS06(#+ VW&1IQ?N#B+LF/774(9[<R%424X #AV9*EZ_'C-K#7N.+,R'M_1C
ME8R(Z[I#.3SI,6!:0T^KPE:F!*9.1^DG4DFNLKQ42V89AH=K!R(/W6-<W@0N
M&USLE* ,ESJ0-2("."%*8FP,8O=(JT,!ST^%1>9O0](Z=U"\P6Y'\ B11-.:
M@:;@BF@7LE"Z_+0%@!Y2IE%DX!(A\$%-A=]YM[#&*C.HOD3)1925))+#MTL&
M=G=A\A1I%.-N-DQ-#/@$0UP8/#["V;D-'.?9RFO87YI;E)KVD(8BO!\.G2$Y
M8(/$&ICSP^XA",4Q\;S7 $T2;XAR:_]Y@E F?#3"=0A#/8]IJIA;#:&\.?H#
M%2*?U=!^7^0Y*S5HP<$[\SL0;X;Z&\!LN!,@2&HBRD.0_I$GFLG$ ,TBDIY&
MESWB\)>&@5_H/RN0/XC $NXGVLLA0M"3/*[PQ/",-#[@*#I=?$,J1LET7\-N
MC% "O):!HB"TZD-FD&&?E7"<]E[.4=W?06[6!XG U9F-O$[P8%#:B_, A?T(
M6>%9E )N,1+_$>#F-#+ FI#U (%(2:I5EIY%]'Z#5.$=R(J(O59?P/"S%6L^
M _7)*XO8^ ;QTST!MZ-$7$[A?:N6_L_6S]N]S<VU91%&NIW&K,CP0*<H$I)1
MVRJ99P<@%E0P'KPS*W*4U0MD4/'=8_:/(7<B@0JEOH/(CM5^GE6V/EQ/]HEL
MI$)Y0,('J6PJ.D.D!O@2$B0@7!,G+]:OVA*D'6/'\+;(B6P>(9$@RH@P\CLD
M4O"7_'I$U@\:GX4.H&(]T9BJJ>A,40SZW(5VDM0EJ( @=L'2$I ^$D1&Q"_
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M"#3 TGOBM8L/Q]7EM0]]X>*=-O</EFB^R4W'BA5Y8T6S^H)B-:?=WX)>E?A
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M1N;9'$9AR;](UUUC#5B+H6',<6*?)**X*AG::<5>(&$G/*;O)>:G0+ $DTQ
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MF^UF1;BE<:;$%1N0.<6$7AX$"X IG8%2AJ0.E4(O/:_N$M!</L0(-D>7N27
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MI_!%$: X-#ZH;Q0"8Z@(TT7GR->MW>#>3EM\XWZY-[#:+?\#4$L! A0#%
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H9"TR,#(U,3(Q,E]P<F4N>&UL4$L%!@     (  @ -P(  "OX      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>ea0269660-8k_relmada_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rlmd-20251212.xsd" xlink:type="simple"/>
    <context id="AsOf2025-12-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553643</identifier>
        </entity>
        <period>
            <startDate>2025-12-12</startDate>
            <endDate>2025-12-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-12-12" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-12-12" id="Fact000004">0001553643</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-12-12" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-12-12" id="Fact000010">2025-12-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-12-12" id="Fact000011">RELMADA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-12-12" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-12-12" id="Fact000013">001-39082</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-12-12" id="Fact000014">45-5401931</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-12-12" id="Fact000015">2222 Ponce de Leon Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-12-12" id="Fact000016">&#160;Floor 3</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-12-12" id="Fact000017">Coral Gables</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-12-12" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-12-12" id="Fact000019">33134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-12-12" id="Fact000020">786</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-12-12" id="Fact000021">629-1376</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-12-12" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-12-12" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-12-12" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-12-12" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-12-12" id="Fact000026">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-12-12" id="Fact000027">RLMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-12-12" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-12-12" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
